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Abstract 
 
Chronic thromboembolic pulmonary hypertension (CTEPH) is an uncommon sequela of acute 
pulmonary embolism and, untreated, leads to right ventricular (RV) failure and death. Despite its 
growing recognition, methods for the detection of early RV insufficiency and prediction of clinical 
deterioration, important to optimum preservation of RV function, are currently suboptimal. 
Furthermore, underlying genetic predisposition to CTEPH, unexplained by defective fibrinolysis, 
remains largely unexplored.  
 
The RV’s physiological response to chronic thromboembolic obstruction is arguably best described 
by RV pressure volume loops which, historically, are best obtained using the conductance catheter. 
Although invasive, conductance has an indisputable advantage over current imaging modalities; 
catheters measure dynamic ventricular pressure and volume throughout the cardiac cycle. Using this 
technique, abnormal RV pressure volume loops are demonstrated in response to chronic thrombotic 
obstruction, independent of resting haemodynamic criteria diagnostic of CTEPH. Pressure volume 
differences and accrual of an exercise gas exchange deficit further suggest early ‘subclinical’ RV 
adaptation. The genetic architecture of CTEPH is also explored using high-throughput sequencing of 
unrelated patients. This shows that rare DNA variants in CTEPH that are predicted to harbour 
deleterious effects are not over-represented in fibrinolytic pathways. Finally, prognostication in 
CTEPH is evaluated using a clinical deterioration model which is shown to be predicted by patient-
reported outcomes at diagnosis. 
 
In conclusion, RV and pulmonary circulatory function in chronic thromboembolic pulmonary 
vascular disease are inadequately characterised by existing routine methods. Links between the 
observed physiological deficits, risk of clinical deterioration and abnormal genetic architecture 
warrant further evaluation in this rare disease. 
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Chapter 1.   Introduction 
 
1.1 Definition and Classification of Pulmonary Hypertension 
 
Pulmonary hypertension (PH) is a severe but rare disorder characterised by increased pulmonary 
vascular resistance (PVR) secondary to progressive obstruction within the pulmonary circulation. It is 
defined by a mean pulmonary arterial pressure (mPAP) >= 25 mmHg at rest assessed at right heart 
catheterisation (RHC). The most updated clinical classification is outlined in Table 1.1 and takes into 
account shared pathological and clinical features (Simonneau et al., 2009). 
 
Table 1.1 
Clinical Classification of PH (Dana Point 2008) 
1 Pulmonary arterial hypertension (PAH) 
    1.1 Idiopathic PAH 
    1.2 Heritable 
        1.2.1 BMPR2 
        1.2.2 ALK1, endoglin (with or without hereditary hemorrhagic telangiectasia) 
        1.2.3 Unknown 
    1.3 Drug- and toxin-induced 
    1.4 Associated with 
        1.4.1 Connective tissue diseases 
        1.4.2 HIV infection 
        1.4.3 Portal hypertension 
        1.4.4 Congenital heart diseases 
        1.4.5 Schistosomiasis 
        1.4.6 Chronic hemolytic anemia 
    1.5 Persistent pulmonary hypertension of the newborn 
1' Pulmonary veno-occlusive disease (PVOD) and/or pulmonary capillary hemangiomatosis (PCH) 
2 Pulmonary hypertension owing to left heart disease 
    2.1 Systolic dysfunction 
    2.2 Diastolic dysfunction 
    2.3 Valvular disease 
3 Pulmonary hypertension owing to lung diseases and/or hypoxia 
    3.1 Chronic obstructive pulmonary disease 
    3.2 Interstitial lung disease 
    3.3 Other pulmonary diseases with mixed restrictive and obstructive pattern 
    3.4 Sleep-disordered breathing 
    3.5 Alveolar hypoventilation disorders 
    3.6 Chronic exposure to high altitude 
    3.7 Developmental abnormalities 
4 Chronic thromboembolic pulmonary hypertension (CTEPH) 
5 Pulmonary hypertension with unclear multifactorial mechanisms 
    5.1 Hematologic disorders: myeloproliferative disorders, splenectomy 
    5.2 Systemic disorders: sarcoidosis, pulmonary Langerhans cell histiocytosis: lymphangioleiomyomatosis, 
neurofibromatosis, vasculitis 
    5.3 Metabolic disorders: glycogen storage disease, Gaucher disease, thyroid disorders 
    5.4 Others: tumoral obstruction, fibrosing mediastinitis, chronic renal failure on dialysis 
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1.1.1   Group 1: Pulmonary Arterial Hypertension (PAH) 
 
Pulmonary arterial hypertension (PAH) makes up Group 1 of the PH classification and is denoted by 
increased pulmonary artery pressure in the absence of left heart disease (McLaughlin and Rich, 2004). 
PAH is predominantly a disorder of distal pulmonary arterioles that demonstrate vessel wall 
remodelling, inflammation, local thrombosis and vasoconstriction. Pulmonary endothelial dysfunction 
produces an inequality between vasoconstricting and vasodilating mediators culminating in increased 
pulmonary arterial smooth muscle cell tone. This occurs in response to excess endothelin-1 levels and 
depleted nitric oxide and prostacyclin levels (Humbert et al., 2004). Vessel wall remodelling is 
stimulated by upregulation of growth factors which act as potent chemoattractants on smooth muscle 
cells and fibroblasts. In hereditary and idiopathic forms, PAH is strongly associated with germ line 
mutations in the gene coding for the bone morphogenetic protein receptor – 2 protein (BMPR2) which 
impair its suppressive effects on pulmonary artery smooth muscle cell growth. Inflammation is 
strongly implicated in the pathogenesis of PAH evidenced by elevated circulating levels of 
inflammatory cytokines (interleukin 1 and 6) (Humbert et al., 1995; Soon et al., 2010), which have 
been shown to predict survival and clinical deterioration (Quarck et al., 2009). 
 
Clinical symptoms in all forms of PH may be non-specific with a typical diagnosis relying on a 
history of progressive exercise intolerance and confirmation of abnormal pulmonary haemodynamics. 
Untreated, PH causes chronic pressure overload of the right ventricle (RV) leading to RV hypertrophy 
and failure. Progressive disease is in part determined by maladaptive neurohormonal signalling, 
inflammatory responses and oxidative stress that accelerate the degree of RV dilatation and failure. 
Prognostic markers include right atrial pressure and cardiac index, acute vasodilator responsiveness, 
functional class, exercise capacity and biomarkers including serum pro-brain natriuretic peptide which 
correlates well with the degree of RV failure (Badesch et al., 2009). PAH-specific therapy consists of 
pulmonary arterial vasodilators which target endothelin, prostaglandin and nitric oxide pathways. 
Multiple randomised control trials have shown these therapies to improve haemodynamic indices and 
functional capacity with epoprostenol and macitentan currently the only agents with evidence for 
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improvement in long term survival (Channick et al., 2001; Galie et al., 2009a; Galie et al., 2005; Galie 
et al., 2008a; Pulido et al., 2013; Rubin et al., 2002; Sitbon et al., 2002). Surgical therapies include 
atrial septostomy and lung transplantation and are only considered in patients with advanced disease 
refractory to medical therapy (Keogh et al., 2009). 
 
 
1.2 Chronic Thromboembolic Pulmonary Hypertension 
 
1.2.1  Definition 
 
Chronic thromboembolic pulmonary hypertension (CTEPH) occupies Group 4 of the Dana Point 2008 
classification and is characterised by unresolved pulmonary thromboemboli associated with 
obliterative destruction and fibrous stenosis of the pulmonary arteries. It differs from PAH in that 
pulmonary artery obliteration is more proximal in CTEPH. A distal arteriopathy is also described 
thought to result from overperfusion of unobstructed lung segments (Hoeper et al., 2006). Similar to 
PAH, CTEPH is haemodynamically defined by a mPAP >= 25mmHg at rest with a pulmonary 
capillary wedge pressure (PCWP)  15 mmHg. Radiologically, CTEPH requires evidence of at least 
one (segmental) perfusion defect that persists following at least three months of therapeutic 
anticoagulation (Moser et al., 1990).  
 
CTEPH is a rare but important complication of acute pulmonary embolism (PE). Traditionally, 
retrospective estimates have suggested it complicates just 0.1% of patients who survive acute PE and 
that a lengthy ‘honeymoon’ period exists between initial presentation and subsequent development of 
symptomatic disease (Fedullo et al., 1995). Subsequent prospective studies have suggested a 
potentially larger disease burden quoting the cumulative incidence of CTEPH at between 1 and 9.1% 
following PE that predominantly occurs within 2 years of presentation  (Becattini et al., 2006; Dentali 
et al., 2009; Fedullo et al., 2001; Pengo et al., 2004; Surie et al., 2010). This wide estimated range in 
prevalence stems from differences in haemodynamic diagnostic cut-offs, patient risk profiles and the 
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inconsistent use of RHC to confirm the diagnosis. Charting the epidemiological behaviour of CTEPH 
remains challenging given that a significant number of patients suffer no prior episode of acute 
venous thrombosis (VTE) and present with sporadic disease (Auger et al., 2004). 
 
 
1.2.2  Aetiopathogenesis 
 
The aetiology and mechanisms of development of CTEPH remain unknown. However, a majority 
consensus has emerged predicated on a theory of disordered thrombus resolution following acute  
VTE/PE. A central theorem is that individuals respond differently to acute thrombotic insult. A recent 
European CTEPH Registry has revealed that previous PE may be detected in 74.8% of patients with 
CTEPH while previous deep vein thrombosis (DVT) is present in 56.1% (Pepke-Zaba et al., 2011). 
The shorfall in patients where no antecedent VTE can be identified is approximately 30% and in 
general, prothrombotic states are not observed in CTEPH. Although prior asymptomatic VTE  is 
recognised (Dartevelle et al., 2004), marked differences in risk profiles exist between patients with 
CTEPH and those with isolated VTE indicating additional unknown factors may be important. 
 
Plasmatic risk factors have been the subject of detailed investigation with traditional prothrombotic 
factors explaining less than 10% of reported CTEPH cases. In particular, deficiency in antithrombin, 
protein C or protein S, all known to predispose to recurrent VTE, share no association (Wolf et al., 
2000).
  
Similarly, mutation in Factor V R506Q (Factor V Leiden) shows no significant association.
 
In 
contrast, high titres of antiphospholipid antibodies have been demonstrated in patients with CTEPH as 
well as increased Factor VIII and von Willebrand Factor antigen levels (VWF:Ag) (Bonderman et al., 
2003; Bonderman et al., 2009; Wolf et al., 2000; Wong et al., 2010). The presence of a lupus 
anticoagulant, strongly associated with recurrent VTE, also accounts for a minority of cases (Auger et 
al., 1995). 
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Non-plasmatic risk factors have emerged from registry data and include previous splenectomy, 
congestive cardiac failure, family history of VTE, inflammatory bowel disease, infected pacemaker 
wires and chronic osteomyelitis (Pepke-Zaba et al., 2011). There are also strong epidemiological 
associations between the development of CTEPH and clinical features at the time of presentation with 
acute PE. These include a larger clot burden, evidence of right heart strain, younger age and 
biochemical evidence of myocardial enzyme leakage at presentation (Lankeit et al., 2008; Pengo et 
al., 2004). Chronic thyroid replacement therapy and a history of malignancy have also emerged as 
novel risk factors (OR 6.10, 3.76 respectively) along with chronic Staphylococcal sepsis (Bonderman 
et al., 2008). 
 
Disordered clot resolution was first implicated in the pathogenesis of CTEPH from experimental 
evidence in dogs where pharmacological inhibition of fibrinolysis potentiated the development of 
chronic organised fibrous material in the pulmonary artery (Moser et al., 1991). This raised suspicion 
that patients with CTEPH may harbour a fibrinolytic genetic defect. Discovery of in vitro 
dysfibrinogenaemia demonstrated patients with CTEPH may have particular fibrin properties that 
confer an enhanced resistance to lysis (Firth et al., 2009; Morris et al., 2006). Rare genetic variants 
within the fibrinogen gene have also been associated with relative resistance to plasminogen-mediated 
fibrinolysis (Linenberger et al., 2000) with our own group demonstrating an over-represented 
fibrinogen A alpha-chain Thr312Ala polymorphism in CTEPH (Suntharalingam et al., 2008). 
However, the effect of such variants in vivo remains unknown and, significantly, no difference exists 
in tissue plasminogen activator (tPA) or plasminogen activator inhibitor – 1 (PAI – 1) levels between 
patients with CTEPH and controls (Olman et al., 1992). Human gene expression studies comparing 
CTEPH thrombi with native pulmonary arterial tissue samples have suggested abnormal regulation of 
pathways involved with proliferation and endothelial function (Lang et al., 1994). In addition, a recent 
underpowered genome wide association study has shown an association between HLA loci B*5201 
and DPB1*0202 in patients with CTEPH (Kominami et al., 2009) although no downstream protein 
target has been identified.  
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Integral to the thromboembolic concept of CTEPH is how the venous system degrades and removes 
large vessel thrombi in the non-diseased state. This involves a complex process of adaptive thrombus 
remodelling, neovascularisation and recanalisation of the pulmonary arterial vessel wall, analogous to 
granulation tissue formation in the healing wound. Recruitment and margination of monocytes and 
neutrophils enhance thrombus clearance and deregulation of monocyte recruitment has been shown to 
be detrimental to this process (Ali et al., 2006; McGuinness et al., 2001). Both cell types recruit 
inflammatory mediators and upregulate growth factor expression including Vascular Endothelial 
Growth Factor (VEGF). This is known to enhance tissue factor-mRNA and protein levels on 
endothelial cells (Mechtcheriakova et al., 1999). Transforming growth factor-beta (TGF-β), 
fibroblastic growth factor (FGF), proteases (matrix metalloproteases/urokinase-type plasminogen 
activator) and chemoattractants including monocyte chemotactic protein-1 (MCP-1) are also 
upregulated during thrombus clearance and appear to accelerate the organisation and resolution of 
venous thrombi (Waltham et al., 2003). However, how these factors interplay to give rise to cellular 
remodelling, inflammation and neovascularisation culminating in delayed thrombus resolution is still 
subject to debate. 
 
 
 
1.2.3  Treatment 
 
The first line therapy for CTEPH is pulmonary thromboendarterectomy (PTE). This involves the 
surgical removal of both recent and chronically organised thrombotic material from the pulmonary 
artery endolumen as well as neointimal and tunica medial resection of the pulmonary arterial wall 
(Figure 1.1). In the only UK centre offering PTE surgery, operative mortality is under 5% with 
considerable importance placed on case selection and preoperative haemodynamic assessment (Freed 
et al., 2008). 
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Figure 1.1 
Pulmonary thromboendarterectomy specimen (reproduced with permission of Mr D Jenkins, 
Papworth Hospital)  
 
 
In inoperable CTEPH, that is disease lying within surgically inaccessible sites usually distal to 
subsegmental level pulmonary arteries, patients may be treated with medical vasodilator therapies 
including prostaglandin analogues (Cabrol et al., 2007), endothelin receptor antagonists (Hoeper et al., 
2005a) and phosphodiesterase V inhibitors (Reichenberger et al., 2007). In separate analyses, 
bosentan, prostacyclin analogues (epoprostenol, treprostinil) and sildenafil have all been demonstrated 
to improve exercise capacity and/or haemodynamic parameters in inoperable CTEPH although not all 
trials have been placebo controlled. More recently, Riociguat, a guanylate cyclase activator, has been 
shown to have a beneficial effect on exercise capacity (Ghofrani et al., 2013). 
 
 
1.3 Functional assessment of the Right Ventricle 
 
1.3.1 Physiology of Right Ventricle and the Pulmonary Circulation 
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Early understanding of the function of the RV regarded it as simply a conduit delivering blood from 
the cavae to the pulmonary circulation. However, in recent decades the importance of the RV as a 
contractile pump has emerged from studying the clinical effects of RV failure, PH and congenital 
heart disease (Dell'Italia, 2012). Often neglected in comparison to the left ventricle (LV), the RV is 
anatomically more complex than its neighbour and due to the fundamental differences between 
pulmonary and systemic circulations, parameters of contractile performance are not directly 
transferable between ventricles (Bellofiore and Chesler, 2013).  This difference is typified by the low 
resistance and high compliance of the pulmonary circulation which maintains pulmonary arterial 
pressure at sub-systemic levels. In contrast, the higher afterload systemic circulation has different 
ventricular adaptive responses to disease (Haddad et al., 2008). This is clearly demonstrated by 
marked differences in response to unloading in the RV and LV, with the former capable of almost 
immediate and sustained reverse remodeling (Mauritz et al., 2012; Rensing et al., 1997). 
 
In health, the RV has a crescentic short axis shape, bound by a thin free-wall and shared 
interventricular septum within a fixed pericardial sac. Its anatomy can be described by three 
components; 1) the inlet consisting of the tricuspid valve apparatus, 2) the trabeculated apical 
myocardium and 3) the infundibulum or RV outflow tract. Prominent internal muscular bands provide 
structural support and attachment to papillary muscles. Under normal loading conditions and electrical 
conduction, the septum is concave toward the LV throughout systole and diastole with RV mass 
measuring roughly one sixth that of the LV. Orientation of myocardial fibres ensure direct mechanical 
interaction between LV and RV, termed ventricular interdependence. Superficial fibres lie 
circumferentially contiguous with the LV at the cardiac apex whereas deep fibres align longitudinally 
from base to apex. This causes a retained contribution from the LV towards RV ejection that can be 
up to 50% under certain loading conditions (Feneley et al., 1985). 
 
Systolic ejection in the RV is sequential with approximately 50 milliseconds separating contraction of 
the inlet myocardium from contraction of the infundibulum (Dell'Italia, 1991). RV shortening is 
greater longitudinally than radially and in contrast to the LV, twisting rotational movements do not 
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make a significant contribution to the generation of forward flow. Volume rather than pressure work 
is performed during RV contraction producing shorter isovolumic contraction times with an early 
pressure peak and rapid fall off. In contrast to the LV, diastolic filling is more prolonged in the RV 
although the isovolumic phase of relaxation is shorter. The heightened sensitivity to changes in filling 
in the thin walled RV signifies its greater chamber compliance than the LV. Under conditions of 
pericardial constraint, this predisposes the RV to earlier decompensation. 
 
In health and at sea-level, the pulmonary circulation has characteristic elastic properties that define its 
physiological behaviour. Small, thin-walled muscular arteries taper out to the pulmonary capillary 
level and ensure a high capacity, low resistance vasculature. The pulmonary circulation therefore 
remains relatively unpredisposed to a hypertensive state in comparison to the systemic circulation; 
indeed, in health, total vascular resistance is roughly 20% of that of the systemic circulation. The 
greater recruitable pulmonary vascular reserve also allows pulmonary arterial pressure to remain 
relatively unchanged despite large increases in circulating blood volume (cardiac output) such as at 
the onset of exercise. This property is used routinely in the clinical assessment of pulmonary 
circulatory function and is defined by the pressure flow relationship in the pulmonary vascular bed 
which describes the resistance to forward flow from the RV: 
 
TPVR = mPAP / Q 
 
where TPVR = total pulmonary vascular resistance and Q = RV cardiac output.  
 
More frequently, the difference between the inflow and outflow pressure of the pulmonary vascular 
bed is calculated by subtracting mean left atrial pressure (LAP) from mPAP. LAP may be 
approximated through use of PCWP providing pulmonary vessels are fully recruited and pulmonary 
capillary pressure is higher than alveolar pressure. Thus, pulmonary vascular resistance (PVR) is 
given by: 
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PVR = (mPAP – PCWP) / Q 
 
This calculation is governed by laws of laminar flow where resistance to flow is a function of the 
product of the length of the tube, l and viscosity constant, η divided by the internal radius of the tube 
to the power of four. PVR is derived most accurately by RHC and neatly describes the constriction 
and dilatation of pulmonary resistive vessels used most commonly in clinical monitoring. 
 
 
 
1.3.2 Conductance Theory and Pressure Volume Loops 
 
Haemodynamic parameters that assume laminar flow in the pulmonary artery form the backbone of 
clinical assessment in PH. However, no consensus exists on the optimal method of RV functional 
assessment which prognostically carries greater importance. In PH (and cardiac transplantation), 
flotation catheters represent the gold standard method of haemodynamic assessment but as far back as 
the 1970s, pressure volume (PV) RV catheterisation has been used as arguably a more sensitive 
indicator of RV function. 
 
First applied in the human RV in 1984 by McKay (McKay et al., 1984), RV PV loop measurements 
are best generated by using conductance catheters. A typical PV loop obtained by a conductance 
catheter placed in the RV is shown in Figure 1.2. Conductance catheters are multipurpose catheters 
with platinum electrodes located at the distal end (Figure 1.3). Through simultaneous recording of 
pressure and volume, these catheters allow the construction of pressure volume loops throughout the 
cardiac cycle. This technique is currently unsurpassed by noninvasive imaging techniques due to the 
detailed beat to beat pressure and volume signals that describe ventricular responses to loading and 
unloading. 
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Figure 1.2 
The normal RV pressure volume loop showing a typical RV triangular morphology. Continued 
Ejection (volume loss) during pressure decline is seen due to the highly compliant pulmonary 
vasculature and momentum of blood in the outflow tract. Separate RV pressure and volume signals 
coordinate with electrical activity on ECG. 
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Figure 1.3 
A custom built pigtail conductance catheter with platinum electrodes located on the distal end. 
 
Conductance catheters generate intracardiac real-time blood volume via a technique exploiting the 
electrical conductivity of blood that emerged in the early 1980s. Conductance theory relies on direct 
measurement of change in intracardiac blood volumes based on the electrical impedance of the time-
varying quantity of blood contained within the ventricular cavity. Blood is a good conductor of 
electricity and the ventricular wall relatively poor. Therefore, when the ventricle is full (at end-
diastolic volume (EDV)), the conductance signal is high in contrast to the end-systolic volume (ESV) 
when conductance will be low. 
 
Intracardiac blood volume-dependent electrical signals are generated using between seven and twelve 
equidistant cylindrical electrodes on the conductance catheter. Intervening electrodes are used to 
measure voltages generated by an alternating current between electrode pairs (30 μA at 20 kHz). The 
blood volume measured between two adjacent sensing electrodes may be considered to be a series of 
stacked cylinders of varying diameters with boundaries defined by the endocardial surfaces of the 
ventricle and equipotential surfaces of the catheter. A change in conductance during ventricular 
contraction in any one of these cylinders is brought about by a change in the resistance between two 
sensing electrodes as a result of the change in cross sectional area of each cylinder. The total 
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ventricular volume is therefore represented by the sum of stacked cylindrical volumes, similar to the 
Simpson’s method used in echocardiography and CMR. The relationship between resistance and 
cross-sectional area of the cylinder is given by: 
 
 R = ρL/A 
where R = resistance, ρ = blood resistivity, L = interelectrode distance, A = cross-sectional area. 
 
Conductivity (G) represents the reciprocal of resistance (G = 1/R) and therefore the time-varying 
conductance of the blood (Gt) within each of the ventricular segments is calculated from the applied 
current divided by the potential difference between consecutive electrodes. The relationship between 
the time-varying volume (Vt) between consecutive electrodes and time varying conductance (Gt) is 
given by the formula below: 
Vt = 1/α .(L2/ρ).(Gt – Gp) 
 
where Vt = time varying interventricular volume, α = dimensionless slope factor (calculated using a 
reference cardiac output – this arises due to non-uniformity of the electrical field within the RV), L = 
inter-electrode distance, ρ = blood resistivity, Gp = conductance of structures outside the ventricular 
blood volume, Gt = time varying conductance. 
 
Inevitable electric field dispersion extends beyond the RV boundary. To correct for this, parallel 
conductance (Gp) extending outside the ventricular blood pool has to be subtracted. Gp is best derived 
by the saline dilution technique whereby a brisk infusion of a bolus of 10% hypertonic saline is 
delivered to the RV to cause a brief increase in ventricular conductance (Baan et al., 1984). The 
apparent increase in RV volume whilst conductivity of surrounding structures remains constant 
(Figure 1.4) enables a theoretical point (A) to be plotted where ESV and EDV are equal and flow 
equals zero. The conductance signal at this point represents that attributable to structures outside the 
RV wall. The derived volume (Vc) is described by the intercept of the EDV/ESV regression against 
the line of identity and is subtracted to give absolute RV volume for each segment.  
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 (A)  
 
 
 
 
Figure 1.4 
Calculation of parallel conductance; the catheter senses an increase in conductivity during hypertonic 
saline wash-in converting an electrical signal to change in V(t). EDV and ESV are then plotted for 
each beat. Linear regression of this line extrapolated to the line of identity intersects at a point where 
ESV = EDV. This volume is due to current conducted through structures surrounding the ventricle. 
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1.3.3 RV applications of Pressure Volume Catheterisation 
 
Arguably the greatest strength of PV catheterisation is the capability to assess load-independent 
contractility of the RV. Contractility is defined by maximal end-systolic elastance (Ees) of the RV 
which is derived from the gradient of the end-systolic pressure volume relationship (ESPVR). This is 
best achieved by obtaining a family of PV loops during preload or afterload alteration (Figure 1.5). 
Frequently this has been achieved by Inferior Vena Cava balloon occlusion but an alternative method 
using single-beat estimation of Ees has emerged offering a less invasive approach (Figure 1.6). The 
single beat method however requires further validation in humans. 
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Figure 1.5 
 
Pressure volume loops generated during preload reduction showing the derivation of ESPVR, the end 
diastolic pressure volume relationship (EDPVR) and Ea which is derived from the gradient of the line 
connecting the end-systolic point and end diastolic point of the PV loop. 
 
Ea 
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Figure 1.6 
 
Single beat estimation of isovolumic Pmax using an extrapolated sinusoidal curve fit. The amplitude 
of the ‘theoretical’ pulmonary artery pressure wave is derived from non-linear extrapolation of the 
early and late systolic isovolumic portions of the RV pressure curve. This is calculated from dP/dtmax 
and dP/dtmin channels (black dots) with Pmax representing a theoretical pressure at maximum peak 
isovolumic contraction (against infinite resistance). The end systolic point (maximum P/V) is used 
with Pmax to derive the gradient Ees. 
 
Effective arterial elastance of the pulmonary artery (Ea) is a parameter that offers a more complete 
assessment of RV afterload than PVR. Ea encompasses resistance, compliance and backward 
reflected waves from branch points in the pulmonary circulation. It is derived from the gradient of the 
line adjoining end-systolic and end-diastolic points of the PV loop (Figure 1.5) and is proportional to 
pulmonary artery wall stiffness (compliance (Ca)). Pulmonary artery compliance can be estimated 
from flotation catheterisation parameters using the pulse pressure method (Ca = stroke volume / 
pulmonary artery pulse pressure) although Ea is a more useful conglomerate of afterload.  
 
The concept of ‘matched’ ventricular and vascular function, so called ‘ventriculo-arterial (VA) 
coupling’ has evolved since its first evaluation from PV loops in an isolated canine heart (Sunagawa 
et al., 1983). VA coupling may be derived by dividing Ees by Ea and describes the energetic 
efficiency of the RV- pulmonary artery interaction (Brimioulle et al., 2003; Maughan et al., 1979; 
Suga and Sagawa, 1974; Sunagawa et al., 1983). Optimal coupling ratios have been identified 
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between 1.0 and 2.0 (Sagawa, 1988) and this relationship demonstrates remarkable cross-species 
conservance (Wauthy et al., 2004). Uncoupling of Ees/Ea to values less than 1.0 is associated with 
high afterload states leading to RV inefficiency and inevitable RV dysfunction. In addition to VA 
coupling efficiency, the conductance technique also offers detailed functional analysis on the systolic 
and diastolic properties of myocardial performance. These are further outlined in Table 1.2. 
  
Conductance 
parameter 
Units Definition Significance Notes 
Systolic     
Stroke Work mmHg.ml Area enclosed by  PV 
loop 
Work performed by the 
ventricle to eject stroke 
volume into 
pulmonary/systemic 
circulation 
Surrogate for 
kinetic energy 
within the RV 
dP/dt max mmHg/s Maximum rate of 
pressure change in 
the RV 
Index of systolic 
contractility/performance – 
a higher value indicates 
better contractility 
Strongly influenced 
by preload, 
afterload, heart rate 
and hypertrophy 
Preload 
Recruitable 
Stroke Work 
(PRSW) 
mmHg/ml Linear regression of 
stroke work with 
EDV.  
Slope of the PRSW 
relationship is highly linear 
and represents ventricular 
contractility. 
Independent of 
preload and 
afterload. Reduced 
slope values signify 
reduced 
contractility 
Ees (ESPVR) mmHg/ml End systolic 
elastance of the 
ventricle. 
Describes the maximum 
pressure developed by the 
ventricle at any given 
volume. Shifts up and 
leftwards with increased 
inotropy. 
Preload/afterload - 
independent 
measure of 
contractility. 
Unaffected by heart 
rate. 
Diastolic     
dP/dt min mmHg/s Maximum rate of 
pressure decline 
Index of diastolic 
relaxation – a higher value 
indicates a more compliant 
ventricle 
Strongly influenced 
by preload, 
afterload, heart 
rate. 
Tau ms Time of exponential 
decay of pressure 
during isovolumic 
relaxation 
Higher values imply 
prolonged relaxation/ 
impaired diastolic filling 
Heart rate 
dependent with 
shortening at 
higher HR. 
EDPVR mmHg.ml Slope of the EDPVR 
represents the 
reciprocal of 
ventricular 
compliance 
Describes passive filling of 
the ventricle by slope of 
minimum EDP for given 
EDV. 
Impaired 
ventricular filling 
results in smaller 
EDV for a given 
EDP. 
 
Table 1.2 
Parameters obtained by conductance catheter and their relative strengths and weaknesses. EDP = end 
diastolic pressure. 
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McKay used a conductance catheter to observe a beat by beat fall in stroke volume following 
Valsalva (McKay et al., 1984). Further early clinical application came in the optimisation of 
pacemaker device settings with description of RV volume in response to heart rate variation and 
arrhythmia control (Khoury et al., 1989; Maloney et al., 1992; Schaldach, 1990). The acute effects of 
RV ischemia on RV PV loop morphology were also derived from conductance (Bishop et al., 1997b). 
Bishop et al showed that right coronary artery occlusion caused an upward leftward movement of the 
end diastolic pressure volume relationship (EDPVR) that normalised on reperfusion thus intimately 
linking RV ischemia with reversible induction of RV diastolic dysfunction. Intra-operative evaluation 
of RV contractility during cardiopulmonary bypass using conductance was subsequently shown to be 
attenuated in the early postoperative phase highlighting important subclinical changes in perioperative 
RV performance (Brookes et al., 1998). The conductance catheter has also been applied to the study 
of valvular heart disease in a pediatric population showing pulmonary regurgitation can be quantified 
by the increase in RV volume during RV diastole (Chaturvedi et al., 1997). In this study, conductance 
showed good agreement with regurgitant fraction measured by magnetic resonance phase velocity 
mapping.  
 
 
Human VA coupling mismatch has been observed in patients with Tetralogy of Fallot implicating a 
maladaptive RV response to chronic volume overload (Latus et al., 2013). Right to left 
resynchronisation of diastole has also been shown to improve RV stroke volume in a patient 
population with CTEPH, indicating dynamic ventricular interdependence communicating via the 
shared septum influences RV performance (Hardziyenka et al., 2011). Conductance catheterisation of 
non-sedated patients with scleroderma-related pulmonary vascular disease recently pointed to intrinsic 
RV systolic dysfunction in scleroderma. This is overlooked by routine haemodynamic assessment and 
suggests primary myocardial involvement in this disease that is not seen on echocardiography 
(Tedford et al., 2013). 
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1.3.4 Cardiac Magnetic Resonance 
 
Cardiovascular magnetic resonance (CMR) is currently considered the non-invasive reference gold-
standard for comprehensive assessment of global RV function. Its advantage over echocardiography is 
the ability to provide multiplanar high-resolution images unaffected by factors such as body habitus, 
concomitant lung disease, and chest wall deformity albeit with increased cost and reduced availability. 
The summation disc method used for calculation of RV volume, mass, and function are highly 
accurate, and reproducible, making CMR well suited for serial follow up (Grothues et al., 2004). 
Other parameters such as ventricular mass index (VMI): the ratio of RV to LV mass are less robust as 
the initial study demonstrating strong correlation with mPAP determined by RHC has not been 
consistently replicated (Roeleveld et al., 2005; Saba et al., 2002). 
Velocity encoded phase-contrast sequence can provide reliable measurements of stroke volume, 
cardiac output and valvular regurgitation. A reduction in the average main pulmonary artery velocity 
to below 11.7 cm/sec has a sensitivity of 92.9% and specificity of 82.4% for detection of PH (Sanz et 
al., 2007). Pulmonary arterial distensibility index can predict the functional capacity with 100% 
sensitivity and 56% specificity when a cut- off value of 10% is used to assess response to vasodilator 
therapy (Jardim et al., 2007). Innovative real-time MRI-guided catheterisation has also been used to 
construct RV pressure-volume loops, which in combination with simultaneously measured pulmonary 
artery flow volumes derived from velocity-encoded cine MRI allows estimation of PVR (Kuehne et 
al., 2004). 
CMR RV data can also be used for prognostication purposes. CMR-derived RV volumes predict 
mortality both at baseline and during follow-up in patients with PH, making CMR an invaluable tool 
for monitoring treatment response (van Wolferen et al., 2007). Other CMR based markers of 
prognosis include paradoxical septal motion which can be visually assessed on cine imaging. 
Myocardial tagging is employed for more objective evaluation of 3-dimensional motion and cardiac 
deformation. Although segmental functional quantification is feasible, it is technically demanding and 
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time consuming and hence not routinely performed. Likewise, it is possible to measure RV diastolic 
functional parameters such as isovolumic relaxation time and diastolic filling but large clinical trials 
are needed for validation.  
Additional information on RV function is also available by studying patterns of delayed contrast 
enhancement using gadolinium. Typically, there is focal enhancement in the insertion of the RV free 
wall into the septum where there is increased mechanical stress (Figure 1.7) (Blyth et al., 2005). The 
extent of fibrosis correlates with RV dysfunction but its prognostic significance is less certain.  
 
Figure 1.7 
Short axis MR image from a late gadolinium sequence in a patient with pulmonary arterial 
hypertension demonstrating focal enhancement in the basal RV insertion sites (thin arrows). The right 
ventricle (RV) is enlarged and hypertrophied with flattening of the inter-ventricular septum. 
 
In spite of its many advantages, the widespread adoption of CMR for routine clinical use is affected 
by reduced availability of equipment and expertise and high cost. Prolonged acquisition times with 
multiple breath-holds hinder its usage in very sick patients. Other pertinent limitations include the 
presence of CMR-incompatible devices such as pacemakers as well as claustrophobia.  
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1.3.5 Echocardiography 
 
Echocardiography is often the first imaging modality to be used on any patient presenting with 
suspected PH. Echo is accessible, safe and cost effective and offers three important non-invasive 
aspects in RV assessment: RV dimensions, RV function and velocity-derived pulmonary artery 
pressures, thereby aiding in diagnosis, risk stratification and monitoring of therapeutic interventions. 
Two-dimensional (2D) imaging of the RV requires the integration of several imaging views due to the 
RV’s complex 3D structure. Thus, calculation of RV volume using 2D echo is limited. 3D echo 
techniques continue to develop and are comparable with the CMR derived gold standard (Figure 
1.8A) (Leibundgut et al., 2010; Niemann et al., 2007; van der Zwaan et al., 2010). Studies have 
consistently demonstrated that RV volumes are 20-34% smaller than MRI. This discrepancy may in 
part be due to limitations of endocardial border detection and tracking capabilities of current software. 
 
A 
Figure 1.8 
RV volumes measured by 3D echocardiography (TomTec (Unterschleissheim, Germany))  
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B 
Figure 1.8 
Eccentricity index measurement from a transthoracic parasternal short axis view in end systole. Red 
arrow (D1) measures left ventricular cavity dimensions and the white arrow (D2) measures dimension 
perpendicular to this plane. Ratio D2/D1 >1 is abnormal and represents RV overload (when in end 
systole, it indicates ‘pressure’ overload; in end diastole, ‘volume’ overload). 
 
Abnormal RV-LV interaction can be assessed by detecting paradoxical interventricular septum (IVS) 
motion. This characteristic helps define the types of diseases that affect the RV. Pressure overload 
causes systolic septum flattening and volume overload causes diastolic septal flattening that can be 
quantified by the LV eccentricity index (LV EI) defined as the inferior-anterior free wall distance 
divided by the septum-lateral free wall distance measured in the short axis at the level of the mitral 
chordal transition. An abnormal EI value that is > 1 results in a D-shaped LV (Figure 1.8B).  
Quantitative volumetric assessment of RV function by 2D echo modalities relies on surrogate markers 
and includes long axis function (M-mode and tissue Doppler imaging), fractional area change and RV 
index of myocardial performance, the latter providing a global estimate of both RV systolic and 
diastolic function since it includes isovolumic periods within its calculations. No single measurement 
has been validated in different conditions and hence a combined approach integrating several 
measurements is advocated (Rudski et al., 2010) 
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Similar to the LV, RV diastolic dysfunction lends important insight into early disease when abnormal 
contractility may not be evident. Diastolic dysfunction is a marker of poor prognosis in many RV 
pathologies and usefully reflects response to pharmacological interventions (Sadler et al., 1992; 
Turhan et al., 2006). Typically a combination of trans-tricuspid inflow Doppler pattern, TDI of the 
basal RV lateral wall and right atrial size helps describe the severity of RV diastolic dysfunction.    
 
 
1.3.6 Multidetector Computed Tomography (CT) 
 
Multidetector computed tomography (MDCT) is not a first line technique for RV assessment but can 
be an excellent substitute when echocardiography and CMR are suboptimal or contraindicated. Unlike 
CMR, CT data acquisition is fast and can be completed in a single breath hold, making it a more 
practical choice for sicker patients. The main limitations of CT are exposure to ionising radiation and 
the need for iodinated contrast medium that can be potentially nephrotoxic and may also influence 
preload and inotropy. 
Non-gated CT pulmonary angiography permits simple structural evaluation such as the diameters of 
systemic veins and pulmonary arteries (indirect measures of preload and afterload), RV dilatation and 
hypertrophy, septal deviation and contrast reflux in the IVC. The addition of ECG-gating allows 
quantitative measurement of cardiac function. Retrospectively gated 3-dimensional CT data yields RV 
volumes, RV ejection fraction and myocardial mass that show good correlation with 
echocardiography, radionuclide scintigraphy and CMR (Coche et al., 2005; Dogan et al., 2006; Guo et 
al., 2010; Plumhans et al., 2008). 3D RV volume measurement on MDCT has been identified as a 
strong predictor of early death in acute PE (Kang et al., 2011) and an RV/LV score > 1.5 is highly 
suggestive of severe RV dysfunction and a poor prognosis (Ghaye et al., 2006; Quiroz et al., 2004). 
However, MDCT has a lower temporal resolution in comparison to CMR and echocardiography and 
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tends to overestimate RV end systolic volume, subsequently underestimating stroke volume and RV 
ejection fraction (Sugeng et al., 2010). 
 
 
1.4 Human Genome Diversity and Genetic Susceptibility in Rare Disease 
 
1.4.1 Background 
 
The human genome consists of roughly 3.2 billion nucleotides, packaged inside cell nuclei as a 
polymer covered by octomeric units of histones. With the exception of identical twins, no two humans 
share identical genomes with on average 0.1% difference in genomic content between individuals. In 
every genome there are approximately 4 million variants termed DNA sequence variants (DSVs) 
which confer factors such as susceptibility to disease, clinical phenotype and treatment responses. 
DSVs can be subdivided into single nucleotide polymorphisms (SNPs) and structural variants (SVs) 
the latter tending to affect greater numbers of nucleotides. This occurs through rearrangements of 
large sections of DNA that may increase or decrease the number of copies of a particular gene. These 
are referred to as copy number variants (CNVs). There are estimated to be approximately 3.5 million 
SNPs per genome of which about 10,000 are likely to be non-synonymous, that is, encode for a 
change in amino acid (Marian, 2012a). A further two thirds of non-synomymous variants are 
predicted to exert deleterious effects on downstream protein products meaning they are of potential 
interest when looking for functionally important variants in complex phenotypes.  
 
In addition to inherited variants, it is estimated that approximately 30 DSVs per whole genome arise 
de novo that is, not inherited from either parent (DePristo et al., 2011). These variants are responsible 
for the continuous introduction of new variants into the genetic pool. Recent rapid expansion of the 
human population within the last few centuries makes it likely that a large number of DSVs are 
relatively new (Tennessen et al., 2012). This is thought to occur because newer alleles have not been 
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subjected to the evolutionary filtering effect of purifying selection. The human genome therefore is 
likely to contain a large (and previously underestimated) number of new and therefore ‘rare’ DSVs. 
Their interaction with more common and by inference ‘older’ DSVs underpins the modern study of 
human genetic susceptibility in complex disease. 
 
Complex phenotypes may result from the additive effects and interactions of both environmental 
factors and numerous causative alleles, each with variable genetic susceptibility effects. These effects 
are likely to range from miniscule to highly significant although the majority most probably lie 
somewhere in between and thus only harbour modest effect sizes (Marian, 2012b). It follows that 
alleles of more recent genetic origin are more likely to have greater effect sizes than older alleles as 
they have been spared selective filtration in successive populations.  
 
By convention, alleles are categorised as common by minor allele frequency (MAF) > 5% , infrequent 
(1-5%) and rare (<1%) in terms of population prevalence. As observed for Mendelian disease, that is 
disorders arising due to a defect in a single gene, DSVs exerting large effects are expected to be rare 
(<1%) (Bamshad et al., 2011; Pritchard, 2001). However, considering rare DSVs as a whole, it has 
also been anticipated that the majority may have weak or no discernible effect. This is akin to the 
most common DSVs in the population which are also likely to harbour only negligible effects. The 
population distribution of rare and common alleles therefore has important bearings on the design of 
genetic studies of complex phenotypes. 
 
Historically, candidate gene approaches based on a priori knowledge of specific genes involved in 
disease pathogenesis have been adopted to examine genetic susceptibility. In IPAH, linkage-based 
analyses of families with multiple affected family members have been able to pinpoint mutations in 
the BMPR2 gene that are responsible for a significant proportion of heritability (Deng et al., 2000; 
International et al., 2000). Where studies of affected family members have not been possible, a 
‘pathway-based’ approach to the selection of candidate genes has been suggested as a potentially 
valuable sequencing strategy. This is based on the apparent clustering of causative variants in 
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different genes on the same or related pathways (Thusberg et al., 2011). Examples include rare 
mutations associated with autism and schizophrenia in multiple genes within neurosignalling 
pathways (Sebat et al., 2007; Walsh et al., 2008). 
 
So called genome wide association studies (GWAS) typically depend on the common disease-
common variant (CD-CV) hypothesis of genetic variation. This predicts that common disease-causing 
DSVs can be found across all human populations which manifest a given disease. The GWAS 
approach uses arrays that focus on common genetic alleles (MAF>5%). However, although GWAS 
have been highly successful in identifying novel disease-associated loci, most associated variants 
confer relatively small increments in risk (OR 1.1-1.5) and taken together explain only a small 
fraction of known disease heritability (Schork et al., 2009). Indeed, for the majority of complex traits 
studied to date, less than 10% of their genetic variance is explained by common polymorphisms 
identified through GWAS (Manolio et al., 2009). Further challenges have been the difficulty in 
identifying functional and causative variants in regions of association, and the uncertain biological 
significance of many variants detected by GWAS. 
 
Attention has more recently shifted to the alternative common disease-rare variant (CD-RV) 
hypothesis which posits that multiple rare variants with larger effect sizes are the principle 
determinant of heritability in complex disease, thus accounting for the ‘missing heritability’ of 
common disease (Eichler et al., 2010; Manolio et al., 2009). These variants are not sufficiently 
frequent to be captured by current GWAS arrays, and their effect size is insufficient to be detected 
through linkage analysis of multiple affected family members. Examples of common conditions 
which have been described in association with multiple, rare large-effect mutations include breast 
cancer, inherited hearing loss, lipid metabolism and neuropsychiatric disorders (McClellan and King, 
2010). 
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1.4.2 Whole exome sequencing 
 
High throughput sequencing has emerged as the principle method of identifying rare variants which 
influence disease risk. High throughput sequencing uses simultaneous polymerase chain reaction 
(PCR) amplification of many hundreds of millions of DNA fragments, physically separated from 
one other, which are then attached to the flow cell of a sequencing platform. These fragments are 
then sequenced in parallel with the flow cell to determine the order of nucleotides in each 
separate fragment simultaneously.  The last five years have seen widespread adoption of this 
technique as a novel approach in human complex disease genetics (Kiezun et al., 2012). This is in part 
due to the precipitous drop in the cost of DNA sequencing and the capability to identify all DSVs 
using this technique, with the possible exception of large CNVs. The approach of whole exome 
sequencing involves selectively sequencing only the complete coding regions of the genome - the 
‘whole-exome’. Although this strategy ignores potentially causative variants in non-coding regions, it 
is widely presumed that the majority of large-effect variants will be located in coding regions (Choi et 
al., 2009). This is supported by studies of monogenic conditions – in which approximately 85% of the 
underlying mutations are located in coding regions or canonical splice sites, as well as strong 
evidence for purifying selection acting most strongly against protein-coding polymorphisms 
(Tennessen et al., 2012). As coding regions comprise only 1-3% of the human genome, whole-exome 
sequencing is a potentially efficient strategy for the identification of rare variants underlying complex 
disease. 
 
1.4.3 Case selection and sequencing strategy 
 
In the last few years, the identification of homozygous or heterozygous mutations in plausible 
biological candidate genes has become possible even from small patient cohorts. This may be applied 
to the study of complex phenotypes with perhaps the most important step lying in the choice of 
samples to be sequenced. In most instances, the greatest potential lies in the sequencing of samples 
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with an extreme outcome, best defined as samples at the extremes of a trait distribution. By excluding 
known modifiers which may include age, sex or comorbidity, the potential genetic contribution to the 
phenotype can be maximised (Guey et al., 2011; Xu et al., 2011). A second approach is to sequence 
the exomes of large cohorts with complex disease, a method which may substantially increase 
statistical power (Kiezun et al., 2012). However, at present, the costs of such projects remain 
prohibitive and given the difficulty collecting sufficient sample numbers in rare conditions, this 
method is restricted to the largest centres. 
 
1.4.4 Quality control and Variant Calling 
 
The processing of high throughput sequencing data requires specialist expertise and computational 
biologists to handle the huge amounts of data generated. Figure 1.10 outlines the principle steps in 
this process.  
 
Figure 1.9 
Typical exome processing pipeline (Ku et al., 2013) 
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Raw sequence reads undergo processing first to ensure that read sequences can be translated into high 
quality genotypes for each sequenced sample. Secondly, filtration of DSVs narrows down the list of 
candidates to more manageable numbers. Numerous methods are available to filter DSVs and 
typically depend on the trait under study, inheritance pattern and study population. However, a 
common goal with each filtration strategy is the aim of pinpointing clusters or even single DSVs that 
lead to pathological protein mutation. One of the most common and powerful filtration steps used in 
familial sequencing involves prioritisation by mode of inheritance. Figure 1.11 shows that 
heterozygote and homozygote DSVs vastly reduce DSV number and can segregate in roughly equal 
numbers.  
 
DSV quality control involves application of bioinformatic steps initially to establish thresholds for 
optimal base calling that assign a confidence that base quality is reliable. Following several quality 
control filters for DNA contamination, short sequence reads are aligned to a reference genome 
allowing calibration of base-quality scores and removal of duplicate reads. This stage allows regions 
that are either poorly mapped or that have low base quality readings to be reprocessed 
computationally. Once overlapping reads have been aligned, variant sites are analysed for differences 
from the reference genome. Machine-learning based classifiers distinguish variants likely to be 
polymorphic from those that represent base call artefacts. Alternatively, a manual approach using 
predetermined quality cut-offs can be used in studies with smaller numbers.  
 
Mapping quality metrics and depth of sequence coverage ultimately determine whether DSVs 
constitute true genetic variation or false positive variation. Further checks are made to ensure the 
number of DSVs per individual are as expected. This may include the number of synonymous and 
non-synonymous variants and the proportion of stop or splice-site variants per individual. Transition-
transversion ratios describe the number of transitions (A to G, G to A and C to T, T to C) in relation to 
the number of transversions (A to C, A to T, G to C, G to T) and should lie over 2.0 for non-
synonymous variants with values over 5.0 expected for synonymous variants (Carr et al., 2013; Isakov 
et al., 2013). 
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Figure 1.10 
Filtration by mode of inheritance acts as a powerful tool to narrow down the genetic target (Majewski 
and Rosenblatt, 2012) 
 
1.4.5 Statistical association analysis relating to rare DSVs 
 
Analysis of rare variants poses challenges and several strategies have been proposed in the recent 
literature (Stitziel et al., 2011). These include aggregation of variants, identification of variants that 
have a causal effect on disease, prediction of their functional consequences, and evaluation of their 
individual and joint contributions to disease. Unlike common polymorphisms, which have typically 
been analysed individually, analysis of rare and unique alleles requires their aggregation as a class and 
then comparison of ‘mutational load’ within the same gene for a given individual. Combining results 
at the gene level, even if different loci are genotyped, can therefore be applied to increase statistical 
power. Bioinformatic tools such as Polyphen are available to classify variants on the basis of likely 
functionality and select variants for statistical analysis that are more likely to have deleterious 
functional effects (Adzhubei et al., 2010). 
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1.7 Aims 
 
This thesis approaches CTEPH from a physiological perspective focusing on early RV adaptation and 
clinical outcome measures in real patients. The genetic architecture of CTEPH is also interrogated 
using a mutliparalleled sequencing approach that stresses the role of rare genetic variation at 
phenotypic extremes in this disorder. The genetic study in Chapter 5 contains preliminary data and the 
discussion places emphasis on data quality rather than raw sequencing output. Two principle 
objectives of the work at outset were as follows: 
 
1. To interrogate the performance of the RV and pulmonary circulation in CTEPH at different 
stages of pathological adaptation using pressure volume assessment of RV function and 
exercise assessment. 
2. To employ a novel methodology to the study of genetic predisposition in CTEPH in attempt 
to further the biological understanding of its aetiology. 
3. To improve prognostic prediction tools in CTEPH using a patient centred approach. 
 
Chapters 1 and 2 include the Introduction and Methods and Materials. Chapter 3 describes an invasive 
catheterisation study of RV function examining the effect of thromboembolic obstruction on 
pulmonary artery and RV performance. The effects of thromboembolic obstruction in patients with 
exercise limitation and normal haemodynamic profiles are further interrogated in chapter 4 using 
cardiopulmonary exercise testing (CPET) to evaluate mechanisms of exercise limitation. In this study, 
the presence of haemodynamically-confirmed PH is shown to be predicted through use of non-
invasive exercise assessment, which may have value in the serial assessment of younger patient 
populations. Exome sequencing data in CTEPH is presented in chapter 5 in a study attempting to 
uncover novel and potentially damaging genetic variation in this disease. Finally, chapter 6 focuses on 
patient-centred outcomes, increasingly relevant to the management of chronic lung disease, which are 
shown to have predictive value on prognosis in two subtypes of PH. 
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Chapter 2.   Material and Methods 
 
2.1 Conductance Catheterisation and Catheter Calibration within the RV 
 
Chapter 3 involves conductance catheterisation of the RV to determine parameters of systolic and 
diastolic RV function and contractility. Conductance catheterisation of the human RV is a challenging 
technique and has been more commonly employed in the study of LV function. RV geometric 
characteristics challenge the assumption that its internal dimensions can be approximated to a series 
of stacked cylinders. However, conductance theory has been extrapolated to the RV (Dell'Italia and 
Santamore, 1998) although to date the majority of clinical RV studies have taken place under general 
anaesthesia. This affords investigators greater control of breathholding required for volume 
measurements during the ventilatory cycle and minimises artifact arising from chest wall movements 
in the awake patient. 
 
 
2.1.1 Method of RV Conductance Catheterisation 
 
Conductance catheterisation of the RV was undertaken immediately following routine Swan-Ganz 
catheterisation (7Fr) via a femoral or jugular approach. Swan Ganz catheterisation was required in all 
study participants as part of their clinical assessment. To calibrate for cardiac output, thermodilution 
was used as the reference derived from the Swan-Ganz catheter. All study participants undergoing 
conductance studies were non-sedated and no haemodynamically altering medications were given 
during any procedure. Prior to placement of the conductance catheter, blood resistivity was 
determined by Rho cuvette. A 6 Fr 8-electrode conductance catheter (Millar Instruments; Houston, 
TX) was inserted through the vascular sheath then advanced under fluoroscopic guidance across the 
tricuspid valve towards the RV apex. Catheters were placed along the longitudinal axis of the 
ventricle to optimise the pressure volume signal. Correct placement was confirmed fluoroscopically 
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(Figure 2.1) and by monitoring segmental volume phase relationships and counter-clockwise pressure 
volume loop genesis. Catheter calibration was performed according to the technique described by 
Baan et al (Baan et al., 1981). Parallel conductance volume (Vc) was measured using the hypertonic 
saline injection technique through a side-channel port. At least two measurements of Vc were made 
using 5mls 10% hypertonic NaCl and the results averaged. The coefficient α was calculated as the 
ratio between conductance catheter-derived cardiac output and the reference cardiac output. Pressure 
volume recordings were acquired at end-expiration during breath hold and only steady state 
measurements were analysed. The proximal end of the conductance catheter was connected to an 
MPVS Ultra signal-conditioning unit (Millar Instruments) and Labchart 7 Pro was used to calibrate 
the conductance signal through a Powerlab 16/30 A-D converter (AD Instruments). 
 
 
Figure 2.1 
Conductance catheter placed via the femoral vein under fluorscopy into the RV 
 
 
2.1.2 Conductance Output Parameters 
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Conductance catheter data were analysed off line by reviewers blinded to patient’s diagnostic group. 
Conductance signals were calculated using the conventional single field excitation which assumes 
homogeneity in the RV electric field. Systolic function was assessed by RV stroke work index 
(RVSWI), dP/dtmax (maximum rate of isovolumic pressure increase) and Ees.  Diastolic function was 
assessed by dP/dtmin (maximum rate of isovolumic pressure decline) and Tau (τ), the time constant of 
isovolumic relaxation. Tau (τ) represents the time constant of isovolumic pressure decay and is 
measured during active myocardial relaxation. It is calculated as a fitted parameter that is exponential 
to the pressure channel data (Weiss' method), using the following equation: p(t)= A.exp(-t/τ) where t 
is time and A is the ‘fitted parameter’. Compliance was calculated using the pulse pressure method: 
conductance-derived stroke volume/pulmonary artery pulse pressure). Single beat estimation of Ees 
was carried out in all study participants using a Matlab sinusoidal curve fit algorithm written to 
estimate theoretical maximum isovolumic pressure from dP/dtmax and dP/dtmin during ventricular 
ejection (Chapter 1, Figure 1.3) (Brimioulle et al., 2003). This program was originally written by 
Professor Anton Vonk Noordegraaf’s research group in Amsterdam and then adapted locally to 
extrapolate from a personalised channel set-up in Labchart 7 Pro.  
Ees was taken as the gradient from theoretical maximal isovolumic pressure (Pmax) to the end-
systolic point. Ea was taken as the gradient from the end-systolic to end-diastolic points of the 
pressure volume loop (Figure 2.2). End-systole was defined as the point of maximum pressure/volume 
toward end-ventricular ejection. Pulmonary valve opening was taken at the onset of ventricular 
ejection following isovolumic contraction. 
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Figure 2.2 
RV pressure volume loop showing parameters of RV – pulmonary arterial coupling, Ees and Ea. The 
ratio Ees/Ea provides an index of the mechanical efficiency of the interaction between RV and 
pulmonary artery. 
 
 
2.2 Cardiac Magnetic Resonance 
 
Chapter 3 involves a volumetric comparison between RV volumes obtained by conductance catheter 
and CMR. CMR imaging was performed on a 1.5-T system (MAGNETOM Avanto
®
, Siemens 
Healthcare, Erlangen, Germany). Images were acquired using a phased-array torso coil with 
retrospective cardiac gating achieved with a vector-ECG system. After initial localiser sequences, 
standard steady-state free-precession (SSFP) technique was used to obtain a contiguous stack of 14-18 
transverse slices (dependent on the size of the heart) covering the RV from the base to apex during 
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breath-holds at end-expiration. The following scan parameters were used: slice thickness 8 mm with 2 
mm slice gap, scan matrix = 200 x 240, flip angle α = 68°, repetition time (TR) 42.6 ms with 15 
segments giving effective TR of 2.84 ms and echo time (TE) of 1.2 ms (iPAT factor 2). The CMRs 
were stored on a Cambridge Computed Imaging (CCI, Cambridge, UK) picture archive and 
communication system (PACS) for subsequent recall and analysis. Measurement of ventricular 
volumes was performed using a certified software package (Q mass ® MR 7.5, Medis Medical 
Imaging system, The Netherlands). Endocardial contours were drawn manually for the RV at end-
systole and end-diastole in each data set as defined by the smallest and largest endocardial areas. The 
method of disk summation was then employed to provide volumetric data for the RV in the axial and 
short axis plane. The moderator band and large trabeculae were included in the myocardial volume 
area with time varying volumes computed at end-systole and end-diastole. 
 
 
2.3 Cardiopulmonary Exercise Testing 
 
Chapter 4 evaluates outcome variables from cardiopulmonary exercise testing. The CPET protocol 
consisted of 1) 2 minutes rest 2) 3 minutes of unloaded pedalling 3) a symptom limited incremental 
exercise protocol using a 5 to 20W/min work ramp on an electronically braked cycle ergometer. Gas 
exchange variables were measured breath by breath and averaged over 20 second  intervals 
(Oxycon
TM
 Pro, Carefusion, UK), in accordance with the American Thoracic Society/American 
College of Chest Physicians Statement on Cardiopulmonary Exercise Testing (Ross, 2003). Work 
ramp was estimated from anthropometric data and patients’ functional impairment so as to attain an 
incremental exercise time lasting 8 to 12 minutes. All patients had to maintain a pedaling frequency of 
60–65 revolutions per minute. Flowmeter and mouthpiece volumes were calibrated prior to each test 
(Bi-directional DVT, Carefusion). Participants were continuously monitored by a 12-lead 
electrocardiogram and pulse oximeter (Radical-7
R
, Masimo). Blood pressure was measured at rest, 
peak exercise and during recovery. Peak aerobic capacity was recorded as the mean value of oxygen 
uptake during the last 30 seconds of the test. Anaerobic threshold (AT) was determined by the V-
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slope method, the lowest ventilatory equivalent for oxygen and end tidal oxygen partial pressure. As 
for peak VO2, AT was averaged over 30 seconds. Vd/Vt was calculated by the Bohr equation (Vd/Vt 
= (PaCO2 – PeCO2)/PaCO2, where PaCO2 is the arterial partial pressure of CO2 and PeCO2 is the mixed 
expired partial pressure of CO2). CPET parameters were analysed at rest, unloaded cycling, anaerobic 
threshold (AT) and peak exercise. Arterial blood gases were all drawn at peak exercise. CPET was led 
independently by a technician who had no knowledge of the results of the RHC used to determine a 
diagnosis of PH. 
 
 
 
 
 
2.4 Whole Exome Sequencing 
 
Chapter 5 involves whole exome sequencing of twenty patients in attempt to uncover novel DNA 
variation that accounts for an underlying genetic aetiology in CTEPH. During this two year period of 
work, rapid developments in sequencing techniques have presented continual challenges to the 
processing, analysis and interpretation of results. These have included improved measures of quality 
control of raw sequence data, resequencing of DNA samples found initially to be of inadequate 
quality and a bioinformatic re-analysis based on several different alignment algorithms. This work 
was undertaken jointly between an external sequencing provider and more recently the Cambridge 
BioResource that runs larger sequencing projects of patients with rare diseases. Following sample 
preparation and DNA extraction, sequencing was initially outsourced to the East Anglia Sequencing 
and Informatics Hub (EASIH) who offer a full DNA quantification and sequencing service. At outset 
in October 2011, 20 patients with CTEPH were sequenced using Agilent’s Version 1.3 exome capture 
kit. It was subsequently decided to extend these results by sequencing parents of CTEPH probands in 
cases where parental DNA was available. This was again undertaken by EASIH and began in 
December 2012.  
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2.4.1 DNA extraction and Exome Capture 
 
Genomic DNA from twenty patients with CTEPH was obtained from frozen whole blood samples 
stored in Papworth tissue bank. Whole blood was transferred from the EDTA tube to a corresponding 
50ml centrifuge tube. The EDTA bottle was rinsed with lysis buffer and contents collected to make up 
a total volume of 40mls. Tubes were spun at 2500 rpm for 10 min following which the supernatant 
was discarded into Trigene solution retaining the white blood cell pellet. The pellet was broken with 
repeat vortexing and re-centrifuged at 2500 rpm for 10 min. Samples were stored at -20C overnight. 
24 hours later, 3.5 ml 6 M
 
GuHCl, 7.5M 
 
NH4Ac, 20% Na Sarcosyl and 50 µl 10 mg/ml Proteinase K 
was used to dissolve the pellet and tubes were incubated in a water-bath overnight. After addition of 
2ml chloroform, samples were centrifuged and the superficial aqueous layer removed with addition of 
a further 2ml of chloroform. Tubes of 10 ml HPLC Grade Ethanol containing the DNA were re-
incubated at -20C overnight and washed for one further cycle. DNA was resuspended in 400µl TE 
buffer depending on pellet size. 
 
Parental DNA was obtained through remote collections of saliva which were returned by post. DNA 
from the saliva was obtained using the Oragene OG-500 DNA self collection system (Genotek Inc., 
Ontario Canada). DNA extraction form saliva was carried out according to the manufacturer’s 
protocol (http://www.dnagenotek.com/ROW/pdf/PD-PR-015.pdf). 
 
DNA was quantified using a Nanodrop spectrophotometer (Nanodrop, Delaware, USA). Quality was 
verified on 0.75% agarose gels. For the Nanodrop, the sample application area was cleaned and 
initialised with 1µl water. 1µl of DNA was applied and the DNA concentration and 260:280 ratio 
determined. (Nucleic acids and proteins have absorbance maxima at 260 and 280 nm, respectively). 
Historically, the ratio of absorbencies at these wavelengths has been used as a measure of purity in 
both nucleic acid and protein extractions. A ratio of ~1.8 is generally accepted as “pure” for DNA; a 
ratio of ~2.0 is generally accepted as “pure” for RNA. As this method does not distinguish between 
52 
 
double stranded DNA or single stranded DNA/RNA therefore, further quantification was undertaken 
using Qubit by EASIH. 
EASIH provided sequencing library construction, exome capture, sequencing, and the initial 
bioinformatic analysis of our study. Following library construction, whole exome enrichment was 
undertaken using the Agilent Sureselect V1.3 sequence capture system which uses custom-designed, 
biotinylated RNA oligonucleotides for hybridization to the target sequence (Figure 2.3) and the 
Human All Exon kit uses 120-mer baits designed to tile across more than 37 Mbp of human genomic 
sequence. 
 
Figure 2.3 
Overview of Agilent’s SureSelect exome capture http://cp.literature.agilent.com/litweb/pdf/5990-
3532EN.pdf). 
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Following hybridization of library fragments to RNA baits, the bound fragments are captured by 
streptavidin-coated magnetic beads, and unbound fragments are washed away. After washing to 
remove unbound DNA, targeted fragments are eluted, amplified and requantified prior to cluster 
generation and sequencing on an Illumina HiSeq 2000 flowcell in 75bp paired-end runs (Figure 2.4). 
 
Figure 2.4 
Overview of the sequencing workflow. Exome capture takes place following construction of 
DNA library, prior to the hybridisation stage. 
 
 
2.4.2 Bioinformatics 
 
In addition to performing targeted exome capture and sequencing, EASIH contributed to 
bioinformatics analysis. This analysis was largely automated from established workflows set up to 
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uncover germ line mutations. Within this, raw sequence data was processed using Illumina's RTA and 
CASAVA pipeline software, which includes image analysis, base calling, and sequence quality 
scoring. Sequencing reads were aligned to human genome assembly GRCh37 using the short read 
aligner, Burroughs Wheeler Aligner (BWA). Read mapping statistics describing capture efficiency 
were derived using GATK. This includes absolute number and percentage of mapped reads on and 
off-target, target region coverage and the percentage of targeted regions that met coverage criteria 
(20x depth). Duplicated sequence reads were marked by GATK and removed in Binary Alignment 
Map (BAM) file format. PCR duplication was quantified for all samples as this can increase the rate 
of false positive variant calls as well as falsely elevating the degree of target coverage. GATK was 
used to perform local realignment and quality recalibration relative to the reference genome. This 
includes corrections of misalignments particularly around insertion/deletion sites which reduces errors 
in downstream DSV calling.  
 
DSVs were called with the Unified Genotyper following variant quality score calibration in GATK. 
Only DSVs with a VQSLOD >/= 5 were taken forward to reduce the false discovery rate. DSVs 
within targeted regions were stored in VCF format and annotated according to variant classification to 
assess function effects on downstream proteins products. This classification included non-
synonymous coding, missense, nonsense, intronic, UTR 5’ and 3’. Analysed datsets were examined 
using the Broad Institute Integrated Genomics Viewer (http://www.broadinstitute.org/igv/) allowing 
visual and comparative analysis of samples. The process of preferentially selecting pathological DSVs 
is described in further detail in Chapter 6.  
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Chapter 3. Right Ventricular Dysfunction in Chronic Thromboembolic 
Obstruction of the Pulmonary Artery 
 
3.1 Introduction 
 
RV function remains the single most important determinant of patient outcomes in PH with 
description of changes in RV volume related to time and pressure arguably the most fundamental 
method of assessment (Champion et al., 2009). The conductance catheter offers simultaneous 
acquisition of pressure and volume on a beat to beat basis (Baan et al., 1981; Baan et al., 1984; Kass 
et al., 1986; Suga et al., 1973) and integrates load-independent indices of forward flow with 
measurement of afterload, a technique widely employed in RV animal models (Brimioulle et al., 
2003; Dell'Italia and Walsh, 1988a, b; Leeuwenburgh et al., 2002; Pagnamenta et al., 2010; Solda et 
al., 1992; Tabima et al., 2010; Wauthy et al., 2005). Ventricular end-systolic (Ees) and effective 
arterial (Ea) elastance may be derived from RV pressure volume loops and a small number of clinical 
studies have suggested predominant homeometric (systolic) RV adaptation in response to high 
afterload (Dell'Italia and Walsh, 1988a; Kuehne et al., 2004; Tedford et al., 2013; Wauthy et al., 
2005). In PH, reduced ventriculo-arterial coupling efficiency (Ees/Ea) has also been estimated non-
invasively using cardiac magnetic resonance (CMR) (Sanz et al., 2012). The assessment of adaptive 
ventricular responses relies on accurate determination of cardiac volume and this study uses beat-to-
beat changes in RV volume derived from a conductance catheter to describe changes in RV 
performance not detectable through use of routine haemodynamics. 
 
CTEPH is characterised by an elevated mPAP due to endothelialised thrombotic obstructions of the 
pulmonary vascular bed that persist despite anticoagulation. However, a proportion of patients 
presenting with chronic thromboembolic obstructions suffer symptomatic limitation despite a resting 
mPAP reading below the diagnostic cut-off for PH (mPAP < 25mmHg). These patients are labeled as 
having chronic thromboembolic disease (CTED) and frequently present with preserved resting RV 
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contractility and near normal cardiac chamber morphology. Routine RHC conducted at rest yields 
limited insight into symptom origins in this disease which may originate in part from early RV 
dysfunction and impaired RV adaptation on exercise (Castelain et al., 2001; Gan et al., 2007). We 
hypothesised that conductance catheter-derived PV loops could expose different resting RV 
mechanics in patients with CTED, specifically arising from subclinical RV dysfunction due to ‘latent’ 
elevation in RV afterload, not incorporated within routine haemodynamics discerned from fluid-filled 
catheters. To reassess the accuracy of RV volumes measured by the conductance catheter, we 
compared conductance catheter-derived volumes in a subset of patients with contemporaneous CMR, 
widely considered to be the current gold-standard method for measurement of RV volume. 
 
 
3.2 Methods 
 
Twenty four patients referred to our Pulmonary Vascular Disease Unit were recruited over 15 months 
for the conductance catheter study. In total, seventeen patients with exertional breathlessness and 
chronic thromboembolic obstruction of the pulmonary artery underwent conductance catheterisation, 
10 of whom fulfilled diagnostic criteria for CTEPH. The remaining 7 had a resting mPAP < 25mmHg 
despite substantial thrombotic burden (Figure 3.1). These patients were labeled as having CTED and 
all had sufficient burden of thromboembolic obstruction to justify invasive haemodynamic assessment 
as judged by their responsible clinician.  
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Figure 3.1 
CMR images in CTED and CTEPH. A: Four chamber still images from a gradient echo sequence in a 
patient with CTED (left) and CTEPH (right). The left hand image displays a normal sized RV in 
comparison to the right hand image showing dilated right heart chambers, RV hypertrophy and septal 
straightening. B: Maximum intensity projection images from a MR pulmonary angiogram from the 
same patients with CTED and CTEPH. Left hand image shows proximal occlusion of left lower lobe 
and segmental middle lobe disease on the right. Right hand image shows proximal web in right upper 
lobe, complex web in right lower lobe and complex web in proximal left lower lobe with attenuated 
anterior segment (block arrow).  
 
 
A further 7 patients who were undergoing closure of a patent foramen ovale (PFO) for prior 
occurrence of minor neurological deficit were used as controls. These patients had an otherwise 
structurally normal heart. 8 patients with either CTEPH or CTED were entered into a sub-study 
comparing RV volumes measured by conductance catheter and CMR performed immediately prior. 
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No control patients underwent CMR. In CTED and CTEPH groups, in order to exclude RV functional 
effects beyond those attributable to thromboembolic obstruction, patients clinically limited by other 
factors were excluded.  This was determined on the basis of the following criteria: FEV1 < 70% 
predicted, FEV1/FVC ratio < 70%, suspected intracardiac shunt, BMI > 30kg/m
2
, history of angina, 
evidence of LV systolic or diastolic dysfunction on screening echocardiogram. 
 
Patients with suspected CTEPH and CTED were all in WHO functional Class II/III. Patients 
undergoing closure of PFO were all assessed as WHO Class I. All patients were admitted to the 
Pulmonary Vascular Disease Unit over a three to four day period during which time baseline 
investigations were made and invasive procedures performed. Anticoagulation was discontinued prior 
to the patient’s scheduled admission. On the day of the RHC, patients eligible for CMR underwent 
scanning as per the protocol described in Chapter 2. Immediately following this, patients were 
brought to the cardiac catheterisation laboratory to undergo RHC in order to match the preload status 
and heart rate as closely as possible between procedures. All patients approached for CMR and 
conductance studies completed both procedures and no patients were withdrawn. Routine blood tests 
including serum NT-proBNP were drawn and a 6MWD was performed in all study participants within 
24 hours of RHC. All patients were in sinus rhythm. 
The principles of the conductance technique and catheterisation methods are described in full in 
Chapters 1 and 2.  In patients with CTEPH and CTED, vascular sheaths were removed at the end of 
the procedure. In control subjects undergoing PFO closure, a general anaesthetic was administered to 
complete the PFO closure according to local protocols. The study was approved by the local research 
ethics committee (Cambridge South REC: 12/EE/0085) and the protocol complied with the guidelines 
of the amended Declaration of Helsinki. All participants gave fully informed written consent. 
 
3.2.1 Statistical Analysis 
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Stata software (Version 12; Stata Corp, College Station, Texas) was used for statistical analysis. 
Conductance data was calculated as the mean values of at least 5 cardiac cycles. Continuous data is 
presented as means ± sd. Comparison between conductance and CMR was assessed by Bland-Altman 
plots. Prior to group comparison, distribution normality of haemodynamic and conductance 
parameters was satisfied by the Kolmogorov-Smirnov test. Conductance data was analysed by patient 
group using repeated measures analysis of variance (ANOVA). When the F ratio of the ANOVA 
reached a critical p value < 0.05, modified T-tests (Scheffe) were used to compare between groups. To 
estimate required group sizes, a minimum clinically important inter-group difference in Tau of 10ms 
(sd 8 ms) was used which, at outset, required 11 subjects in each group (α = 0.05, β = 0.20) (Hoole et 
al., 2010). 
 
 
3.3 Results 
 
3.3.1 Intergroup demographics and haemodynamics 
 
Patient demographics and clinical characteristics were well matched between groups and are shown in 
Table 3.1. Exercise capacity assessed by 6MWD was reduced in CTEPH and CTED groups but not in 
controls. 6MWD showed no relation to mPAP (r=-0.03, p=0.97) although mPAP and serum NT-
proBNP were strongly related (r=0.72, p<0.001). Oxygen saturations across right heart chambers and 
atrial pressures at RHC confirmed no inter-atrial shunting was present in patients with PFOs prior to 
the conductance study and closure of the PFO. Statistically significant differences were observed 
between the CTEPH group and the CTED and control groups for mPAP, RV end diastolic pressure 
(RVEDP) and PVR (Table 3.1). However CTED and control groups were indistinguishable by routine 
RHC data. 
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Controls 
N = 7 
 
 
CTED 
N = 7 
 
CTEPH 
N = 10 
    
Age, yr 48 ± 10 51 ± 16 50 ± 12 
Sex 3F:4M 4F:3M 4F:6M 
BMI, Kg/m
2
 24.3 ± 1.3 26.2 ± 1.9 26.9 ± 2.9 
WHO Class I/II/III 7/0/0 0/7/0 0/7/3 
6MWD, m 556±98 411 ± 62* 393 ± 121* 
Hb, g/dl 14.0±0.9 14.0±1.4 14.8±0.6 
Cr Cl, ml/min 91±13 102±37 99±18 
NT proBNP, pg/ml 21 ± 17 57 ± 23 679 ± 1105 
Concomitant disease 
-Systemic hypertension 
-Diabetes 
-Ex Smoker 
 
1 (17%) 
- 
2 (33%) 
 
1 (13%) 
- 
1 (13%) 
 
2 (20%) 
- 
2 (20%) 
    
RHC haemodynamics 
-RA mean 
 
5 ± 2 
 
5 ± 2 
 
7 ± 2 
-RV EDP 5 ± 2 5 ± 3 8 ± 2*† 
-mPAP 15 ± 3 17 ± 5 43 ± 10*† 
-PCWP/LAP 7 ± 2 7 ± 3 8 ± 3 
-SvO2, % 76 ± 3 75 ± 4 72 ± 6 
-CI, l/min/m
2
 3.2 ± 0.5 2.9 ± 0.3 2.5 ± 0.3* 
-SV (td), ml 87 ± 6 80 ± 6 74 ± 5 
-PVR, dyn/s/cm
5
 110 ± 43 124 ± 39 547 ± 242*† 
    
Table 3.1 
Demographic and Haemodynamic data from RHC prior to conductance study. All pressures in 
mmHg. * P < 0.05 compared with Controls, † P < 0.05 compared with ‘CTED.’ Td = thermodilution 
 
 
 
 
3.3.2 Conductance catheter study of CTED, CTEPH and control patients 
 
Typical morphologies of RV pressure volume loops by group are shown in Figure 3.2. Control 
patients displayed triangular loops with poor distinction of the end-systolic point compared to patients 
with CTED and CTEPH. During systolic ejection (from pulmonary valve (PV) opening to end-systole 
(ES)), the pressure differential (δP) discriminated controls and CTED groups (mean δP = -6.3 ± 3.0 
(controls), 3.2 ± 3.5 (CTED) and 20.4 ± 18.4 (CTEPH) mmHg respectively), (controls vs CTED, p = 
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0.03). δP significantly correlated with mPAP (r = 0.61, p < 0.01), PVR (r = 0.63, p < 0.01), serum 
NT-proBNP (r = 0.70, p < 0.001) and pulmonary artery compliance (r = -0.55, p = 0.01). 
 
 
Figure 3.2 
A  Typical pressure volume loops generated by conductance catheter in the RV during end-expiratory 
breathhold. Control patients (left) demonstrate triangular RV loop morphology in comparison to 
CTED (middle) and CTEPH (right) groups.  B  Pressure differential (δP) during systolic ejection from 
pulmonary valve (PV) opening to end systole (ES) discriminates disease groups. PV = pulmonary 
valve, ES = end-systole. 
 
 
Numerical conductance data is displayed in Table 3.2. RV diastolic parameters showed that Tau was 
significantly prolonged in patients with CTED and CTEPH compared to controls (p = 0.02). Absolute 
dP/dtmin was highest in patients with CTEPH. dP/dtmin showed strong correlation with serum NT-
proBNP (r = -0.61, p<0.01). In the CTEPH group, systolic contractility was higher as defined by 
RVSWI, dP/dtmax and Ees. Higher Ees was linearly related to elevated Ea (R
2
 = 0.73, p < 0.001) and 
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inversely correlated to pulmonary artery compliance (r = -0.58, p = 0.01) and 6MWD (r=-0.47, p = 
0.03). VA coupling index (Ees/Ea) was lowest in patients with CTEPH and showed a strong inverse 
relationship to mPAP and PVR (r = 0.75, p < 0.001). Ees/Ea also showed modest but significant 
correlation with serum NT-proBNP (r = -0.54, p = 0.01). The coefficient of variation for estimated 
values of Pmax in each patient used to determine Ees lay within a 10% limit.  
 
 
 
Table 3.2 
 
Conductance Catheter data by patient group. * P < 0.05 compared with Controls, † P < 0.05 compared 
with CTED. Bracketed values subject to inaccuracy (see Discussion). sb = single beat. 
 
 
 
Conductance Parameter 
 
 
Controls 
(n = 7) 
 
 
CTED 
(n = 7) 
 
 
CTEPH 
(n = 10) 
   
 
Haemodynamic Indices 
  
 
RV Pressure (sys), mmHg 31.0 ± 5.6 35.4 ± 3.4 77.2 ± 11.8*† 
RV Pressure (edp), mmHg 4.8 ± 1.4 5.0 ± 1.3 7.6 ± 1.6*† 
Pmax (est. using sb model) 43.1 ± 10.4 52.9 ±6.7 98.6 ± 19.6*† 
Heart rate, beats/min 71.4 ± 11.7 72.2 ± 8.6 72.0 ± 11.0 
 
  
 
Volumes 
  
 
End systolic volume, ml (80 ± 41) (55 ± 43) (60 ± 30) 
End diastolic volume, ml (165 ± 39) (127 ± 55) (143 ± 38) 
Stroke Volume, ml 83 ± 20 74 ± 21 69 ± 17 
 
  
 
Systolic Indices 
  
 
RVSWI, mmHg.ml/m
2
 603 ± 179 653 ± 209 1114 ± 402*† 
dP/dtmax, mmHg/s 394 ± 52 423 ± 124 638 ± 235*† 
Ees, mmHg/ml 0.44 ± 0.20 0.59 ± 0.15 1.13 ± 0.43*† 
 
  
 
Diastolic Indices 
  
 
dP/dtmin, mmHg/s -265 ± 40 -435 ± 79 -733 ± 143*† 
Tau, ms 56.2 ± 6.7 69.7 ± 10.0* 67.9 ± 6.2 
 
  
 
Pulmonary arterial afterload 
  
 
Ea, mmHg/ml 0.30 ± 0.10 0.52 ± 0.24 1.92 ± 0.70*† 
PA compliance, ml/mmHg 5.7 ± 1.5 4.7 ± 1.6 1.76± 1.05*† 
 
  
 
Ventriculo-arterial coupling 
  
 
Ees/Ea 1.46 ± 0.30 1.27 ± 0.36 0.60 ± 0.18*† 
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3.3.3 Conductance and CMR subgroup analysis 
 
RV volumes for individual patients undergoing both CMR and conductance are shown in Table 3.3. 
 
 Haemodynamics RV volumes (ml) 
ID Sex Age Diagnosis 
RA 
mean 
RV 
EDP 
mPAP PCWP 
SvO2 
% 
CI 
L/min/m2 
PVR 
Dyn/s/cm5 
EDV 
CMR 
EDV 
C 
ESV 
CMR 
ESV 
C 
SV 
CMR 
SV 
C 
 
1 
 
M 
 
28 
 
CTEPH 
 
6 
 
7 
 
32 
 
8 
 
71.7 
 
2.2 
 
419 
 
208 
 
123 
 
101 
 
24 
 
107 
 
99 
2 F 64 CTEPH 12 12 46 9 58.9 1.8 928 285 283 219 242 66 42 
3 M 34 CTEPH 6 8 41 6 73.6 2.6 622 274 106 189 50 85 56 
4 F 48 CTEPH 6 6 51 12 71.8 2.5 700 150 135 78 75 72 61 
5 F 52 CTEPH 4 5 44 6 76.3 2.6 661 146 171 101 117 45 53 
6 M 57 CTED 5 4 15 7 78.0 2.3 157 189 101 105 23 84 78 
7 F 69 CTED 5 6 16 10 72.9 2.5 133 88 87 31 36 57 52 
8 M 42 CTEPH 9 11 27 10 74.5 2.9 289 148 - 60 - 88 88 
    Mean ± sd 186±68 144±67 111±63 81±78 76±20 66±20 
 
 
Table 3.3 
 
 
Patient diagnosis, haemodynamics and RV volumes by CMR (Axial plane) and conductance catheter 
(C) 
 
 
 CMR volumes from axial and short axis planes showed strong correlation for end-diastolic (r=0.98), 
end-systolic (r=0.97) and stroke volume (r=0.96). Mean heart rates during CMR and conductance 
catheterisation were not significantly different: 73.2 vs. 75.4 beats per min respectively (p = 0.75). 
Stroke volume between CMR and conductance catheter showed a mean difference of +9ml (95% CI -
1 to 19ml) (Figure 3.3, top), indicating that conductance stroke volume was smaller than CMR stroke 
volume. Larger biases of +48ml (95% CI -16 to 111ml) for EDV and +37ml (95% CI -21 to 94ml) for 
ESV were observed (Figure 3.3, middle and bottom). Markedly lower values for EDV and ESV were 
observed in CTED and CTEPH groups compared to controls. In one patient (ID 8, Table 3.3), 
significant overestimation of Vc resulted in a negative absolute ESV although stroke volume was still 
determinable. Mean Vc and α across our 8 patient subset was 86 ± 14mls and 0.35 ± 0.08 
respectively.  
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Figure 3.3 
Bland-Altman plots of CMR RV volume measurements vs Conductance measurements. Top: stroke 
volume (SV), Middle; EDV, Bottom; ESV. Thickened black line indicates bias, dashed lines indicate 
95% confidence interval. Conductance underestimated EDV and ESV in comparison to CMR whereas 
SV showed better agreement. 
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3.4 Discussion 
 
Our results yield novel insight into the RV’s dynamic performance in response to chronic pulmonary 
thromboembolic obstruction. Changes in PV loop morphology in CTED, most notable during systolic 
ejection, result from elevated RV afterload that develops exclusive of haemodynamic definition of 
PH. In addition, the RV relaxes more slowly in patients with CTED and CTEPH as defined by Tau. 
Discrimination in RV diastolic performance between CTED and controls potentially signifies diastolic 
maladaptation in the RV which in tandem with decreased pulmonary artery compliance may 
contribute to symptom origins in this condition. Our data for the first time describes homeometric RV 
adaptation in response to high afterload in CTEPH. This reaffirms the association between elevated 
RV haemodynamics and reduced ventriculo-arterial coupling efficiency found in previous clinical PH 
studies (Kuehne et al., 2004; Sanz et al., 2012; Tedford et al., 2013). 
 
 
3.4.1 Intergroup conductance study 
 
Conductance catheterisation showed ‘left ventricularisation’ in PV loop morphology in CTED and 
CTEPH compared to controls; patients with CTED continue to develop RV pressure during systolic 
ejection similar to CTEPH where increased resistance and lower arterial compliance is exposed to the 
RV early after pulmonary valve opening. By contrast, control subjects show rapid dissipation in 
pressure during systole with ejection into a more compliant pulmonary circulation. This may be 
explained by abnormal afterload elevation in CTEPH and to a lesser extent in CTED (Bishop et al., 
1997a). Ea did not statistically differ between CTED and controls which may in part be due to small 
numbers in each group and its wide standard deviation. However, the trend towards higher Ees in 
CTED suggests early systolic adaptation in response to higher afterload. We quantified RV 
performance during systolic ejection using δP which is a function of Ea and demonstrated a 
relationship to disease severity across all patients (NT-proBNP). δP significantly correlated with PVR 
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and pulmonary artery compliance which reinforce its association with RV afterload in our patient 
cohort.  
 
In CTEPH, slower RV relaxation measured by Tau can be attributed to chronic elevation in RV 
afterload and lower arterial compliance. The RV in CTEPH is stiff which is in keeping with 
steepening of the end-diastolic pressure volume relationship in experimental models of heart failure 
and following pulmonary artery banding (de Man et al., 2012; Leeuwenburgh et al., 2002). Notably, 
Tau was also prolonged in the CTED group. This is unlikely to be entirely explained by RV afterload 
given broadly similar Ea values in CTED and controls. RV diastolic function may be functionally 
sub-classified by either a decrease in passive myocardial diastolic compliance or impairment in active 
RV relaxation. These phases are inter-related and normal diastolic function is dependent on both 
(Tabima et al., 2010). Given statistically similar values for Ea and pulmonary artery compliance 
between control and CTED groups, we speculate that our CTED group harbour intrinsic RV diastolic 
dysfunction in addition to ‘latent’ elevation in afterload suggested by δP. This is further supported by 
borderline elevation in absolute dP/dtmin in CTED compared to controls, groups that were well 
matched by preload. The markedly elevated absolute dP/dtmin in CTEPH, suggesting more rapid 
dissipation in RV pressure at onset of diastole, is likely attributable to elevated preload (RVEDP) in 
this group, as dP/dtmin is known to be load-dependant (Leeuwenburgh et al., 2002). 
 
3.4.2 RV Volume physiological analysis 
 
Our data suggest poor determination of absolute EDV and ESV using a conductance catheter in the 
human RV, but more accurate determination of stroke volume was achieved. Previously, considerable 
attention has been placed on the accuracy of conductance-derived RV volumes due to increased 
myocardial trabeculation and its crescentic short-axis shape. Both of these factors can disrupt the 
uniformity of the conductance field. The observed underestimation of EDV and ESV may be 
attributable to Vc calculation which appeared overestimated in our patient subset. This results in 
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inappropriate leftward displacement of the PV loop along the volume axis resulting in 
underestimation of absolute volumes. However, stroke volume remains relatively unaffected by Vc.  
 
Higher absolute volumes in control subjects may have arisen from volume variation due to catheter 
position using either the jugular or femoral approach. Catheter insertion from an internal jugular 
approach results in closer catheter opposition to the RV free wall compared to a femoral approach 
where the catheter lies more central to the RV long axis (Figure 3.4). Out of clinical necessity, control 
patients were exclusively studied via a femoral approach compared to only one patient in CTED and 
CTEPH groups. Dual jugular and femoral approaches have not been previously reported in humans 
and we speculate that a more centrally placed catheter may offer improved interrogation of the RV 
outflow tract resulting in improved ‘capture’ of the RV geometry (Brookes et al., 1998; Kornet et al., 
2000). Although not tested in our setting, it has also been suggested dual-field excitation catheters 
improve the electric field uniformity (Danton et al., 2003), but, to our knowledge, this has not been 
substantiated in the human RV. 
 
Fig 3.4 
Jugular insertion (left) results in closer apposition of the conductance catheter to the RV free wall 
compared to use of the femoral approach (right). 
68 
 
3.4.3 Mechanisms of impaired diastolic relaxation 
 
One possible origin of diastolic impairment in CTED and CTEPH may be RV ischaemia. Akin to the 
ischaemic cascade in the LV, RV diastolic impairment may be induced by right coronary artery 
occlusion and so may be driven by a myocardial oxygen supply demand imbalance (Bishop et al., 
1997b). In support of our findings, isolated RV diastolic dysfunction has been purported in a 
connective tissue disease population with normal resting haemodynamics through stress-induced 
effects on subendocardial fibres (Faludi et al., 2008). Animal models of early RV dysfunction have 
also been associated with metabolic remodeling in the RV myocardium where myocardial genetic 
profiling points to abnormal energy substrate use that is partly independent of chronic pressure 
overload (Gomez-Arroyo et al., 2013). Very recently, increased collagen and stiffening of RV 
cardiomyocyte sarcomeres have been implicated in diastolic dysfunction in the human RV in PH 
(Rain et al., 2013). Future investigations detailing RV functional assessment with tissue gene 
expression and metabolomics may perhaps offer clearer explanation of our findings. 
 
 
3.4.4 Clinical implications 
 
Currently the natural history of CTED is poorly defined and it is unproven that patients with CTED 
deteriorate over time. However, a predisposition to RV diastolic dysfunction observed in our study 
offers novel insight into the clinical trajectory of patients with chronic thromboembolic obstruction 
who may be at risk of deterioration. A normal/near normal resting haemodynamic profile fails to 
account for symptom limitation in this condition suggesting haemodynamic abnormalities may only 
manifest on exercise. This has to date been investigated in a similar patient population who 
demonstrate reduced exercise pulmonary arterial compliance following pulmonary endarterectomy 
despite normalisation of PVR (Bonderman et al., 2011). Pulmonary endarterectomy is an established 
treatment for CTEPH and almost universally leads to reverse remodeling of the RV. However, this is 
often incomplete suggesting additional mechanisms of RV dysfunction beyond an increase in 
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afterload may be contributory. Our data suggest a predisposition to primary diastolic RV dysfunction 
in CTED and we speculate that patients with CTED may derive uncertain benefit from pulmonary 
endarterectomy which is currently offered for symptomatic benefit (van der Plas et al., 2010).  
 
3.4.5 Limitations 
 
Our study population derives from a pool of highly selected individuals referred to a tertiary centre for 
invasive haemodynamic investigation. Therefore, although the dataset is small and carries risk of 
Type II error, groups were necessarily selected to minimise confounding effects on RV mechanics 
from conditions such as COPD, LV dysfunction and obesity. Caution should nevertheless be 
exercised in extrapolating our results to a ‘real-world’ population with CTED in whom comorbidities 
may be prevalent. Secondly, RV volume determination using a conductance catheter is challenging 
with potential error arising from a non-uniform electric field due to fall off in equipotential planes at 
the extremes of the ventricular boundary. However, our study attempts to address the accuracy of 
conductance RV volumes in humans using temporal comparison with the most up to date gold-
standard method, CMR. In doing so, we have shown acceptable agreement between conductance and 
CMR techniques for stroke volume determination suggesting conclusions drawn from PV loop 
dimensions are robust. 
 
Simultaneous right and left ventricular haemodynamic and volume indices were not measured during 
conductance meaning we cannot comment on ventricular interdependence. However, no patients in 
our study had echocardiographic evidence of LV systolic or diastolic dysfunction and all had normal 
pulmonary capillary wedge pressures making a LV contribution to our diastolic findings unlikely. We 
employed a single beat methodology to derive an estimated Pmax, which relies on mathematical 
assumptions derived from a large mammal model. To date, this method remains unvalidated in the RV 
of patients with PH although with use of a Valsalva manoeuvre to alter cardiac load, Ees has recently 
been generated by a family of loops (Tedford et al., 2013).  Lastly, our protocol did not enable wave 
reflection measurement which may have been contributory to our observations on RV afterload. 
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3.5 Conclusions 
 
Comprehensive RV assessment by conductance catheterisation detects novel alteration of PV loop 
morphology and delayed RV relaxation in patients with CTED. However, when referenced to CMR, 
our method provides suboptimal determination of absolute RV volume. Abnormal resting RV 
mechanics demonstrated by conductance signify functional adaptation in the RV in thromboembolic 
obstruction which warrants further evaluation in future studies to establish downstream clinical 
effects.  
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Chapter 4.  Inefficient exercise gas exchange identifies pulmonary 
hypertension following pulmonary embolism in patients with chronic 
thromboembolic obstruction  
 
4.1 Introduction 
Chronic thromboembolic pulmonary hypertension (CTEPH) is an uncommon sequela of acute 
pulmonary embolism (PE) (Becattini et al., 2006; Dentali et al., 2009; Klok et al., 2010; Miniati et al., 
2006; Pengo et al., 2004; Poli et al., 2010) although within a CTEPH patient population, antecedent 
PE may be present in up to 75% (Fedullo et al., 1995; Pepke-Zaba et al., 2011). Patients present with 
effort dyspnoea predominantly related to incapacity of the RV to increase cardiac output on exercise. 
Untreated this condition typically leads to progressive RV dysfunction so early detection, ideally 
using non-invasive methods, prior to physiological decompensation may be advantageous.  
Patients with CTEPH present with effort dyspnoea however, a proportion demonstrate mPAP values < 
25mmHg at rest despite the presence of persistent chronic pulmonary thromboembolic obstructions. 
As described in Chapter 3, these patients may be labelled with CTED and usually present with 
preserved resting RV contractility and normal cardiac chamber morphology. Hence, investigations 
conducted at rest such as echocardiography may lack power to detect changes suggestive of 
progression to CTEPH. Assessment of potential attenuation in cardiac output on exercise therefore 
requires an exercise-based assessment method.    
Cardiopulmonary exercise testing (CPET) demonstrates a characteristic profile in PAH (Hansen et al., 
2004; Sun et al., 2001). However patients with chronic thromboembolic obstruction are less well 
described.  6MWD reflects haemodynamic severity in CTEPH but does not inform on mechanisms of 
exercise limitation (Reesink et al., 2007). Therefore, we hypothesised that CPET could be used to 
differentiate the exercise profiles of patients with CTED and CTEPH compared to sedentary controls. 
Following this, we aimed to establish which exercise parameters were predictive of a diagnosis of 
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CTEPH and potentially therefore of value in the follow up of patients with unresolved PE who are at 
risk of deterioration. To account for a potential association between proximal thrombotic burden and 
pulmonary haemodynamics, we quantified thrombotic obstruction in these groups to evaluate for any 
effect of greater thrombotic load.  
 
4.2 Methods 
Patients underwent incremental symptom-limited CPET and RHC within 72 hours. Radiological 
evaluation with CT pulmonary angiogram was carried out prior to RHC in patients with CTED and 
CTEPH to confirm a radiological pattern consistent with chronic thromboembolic obstruction. 
Patients with chronic thromboembolic obstruction were grouped by diagnosis following RHC: mPAP 
>= 25mmHg (CTEPH), mPAP < 25mmHg (CTED) and compared with age and sex-matched 
sedentary controls (Controls). Eligibility for study enrolment was determined following patient 
referral to our unit with a suspected diagnosis of CTEPH. As a prerequisite, study patients had to be 
symptomatically limited with evidence of chronic thromboembolic obstruction on CT pulmonary 
angiogram after PE despite at least 6 months anticoagulation with documented treatment compliance. 
CT pulmonary angiography was undertaken in either the patient’s local institution or our own and in 
all cases was preceded by at least 6 months anticoagulation. All patients were anticoagulated at study 
entry.  
In total, thirty patients were recruited over thirteen months. 5 patients were not enrolled due to 
screening failure (see Figure 4.1). One such patient was not enrolled due to lack of thromboembolic 
disease on CT pulmonary angiography following repeat CT scan at our institution. All patients 
enrolled completed the CPET and RHC and no patients were withdrawn. Asymptomatic age and sex 
matched sedentary controls underwent incremental CPET only. The CPET protocol is as described 
within the Methods: Chapter 2. The study was approved by the local research ethics committee 
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(Cambridge South Ref 12/EE/0085) and the protocol complied with the amended Declaration of 
Helsinki. All study participants gave written informed consent prior to study enrolment. 
Patients clinically limited by factors other than chronic thomboembolic obstructions were excluded.  
This was determined on the basis of the following factors: FEV1 < 70% predicted, FEV1/FVC ratio < 
70%, suspected intracardiac shunt, BMI > 30 kg/m
2
, history of angina, evidence of LV systolic or 
diastolic dysfunction on echocardiogram. In addition patients unable to perform cycle ergometry were 
excluded. The enrolment pathway of patients is summarised in Figure 4.1. 
 
Figure 4.1 
Patient enrolment pathway: exercise study 
 
4.2.1 Radiological evaluation 
We used a modified Qanadli Index to quantify proximal chronic thromboembolic obstruction as 
previously described (Hoey et al., 2011). Briefly, a maximal score of 2 was assigned for a patent 
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segmental artery and its first order subsegmental branches, giving a total possible score of 40 (three 
branches to both upper lobes, two branches to the middle lobe and lingula, and five branches to both 
lower lobes). One point was subtracted if there was clear evidence of subsegmental disease, a 
segmental web stenosis, or segmental partial occlusion. If two or more of these abnormalities were 
present, a score of 0 was assigned to that segment. Segmental total occlusion was also assigned a 
score of 0. Laminated thrombus of the main or lobar arteries that exceeded 50% of luminal reduction 
necessitated the subtraction of 1 from the scores for all segmental arterial branches distal to this point. 
Total vascular obstructive (TVPO) index was calculated by dividing the patient score by 40 and 
multiplying the result by 100. Scores therefore represent a percentage of normal (patent) segmental 
arteries in that patient. 
4.2.2 Statistical Analysis 
Averaged data are presented as mean ± sd (parametric variables) and unpaired Student’s t-test was 
used to compare between parametric datasets. Non-parametric data was summarised as median and 
interquartile range. Mann-Whitney test was used to compare non-parametric data. Values of p < 0.05 
were considered significant. The capacity of CPET parameters to predict a diagnosis of CTEPH was 
analysed using univariate and multivariate logistic regression. Variables demonstrating discriminatory 
value between CTED and CTEPH groups with biological plausibility were analysed. A threshold of p 
< 0.10 was set prior to logistic post-estimation receiver operating characteristics (ROC) analysis. In 
all cases the area under the curve (AUC) was compared with a value of 0.50 and the highest 
sensitivity and specificity of the predictor variables determined. Statistical analysis was performed 
using Stata Version 12 (Stata Corp, College Station, TX). 
 
4.3 Results 
4.3.1 Patient characteristics 
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Demographics and RHC data are shown in Table 4.1. At RHC, 15 patients fulfilled diagnostic criteria 
for CTEPH. A further 15 had a resting mPAP < 25mmHg despite substantial thrombotic burden. 
Compliance, estimated using the pulse pressure method, was lower in CTEPH. There were 12 ex-
smokers in total although none had greater than a 10 pack year smoking exposure. No patients with 
CTED or CTEPH were taking supplemental oxygen. Patients with CTED and CTEPH suffered both 
acute and recurrent PE in our cohort. This is further described in Table 4.2. No control subjects 
reported symptoms consistent with cardiopulmonary disease. 6MWD performed was not different 
between patients with CTED or CTEPH (p = 0.22). 
    
 
Controls 
N = 10 
CTED 
N = 15 
CTEPH 
N = 15 
    
    
Age 46 ± 11 53 ± 17 54 ± 13 
BMI  25.1 ± 2.6 26.5 ± 2.7 26.8 ± 3.3 
Female/Male 6:4 8:7 7:8 
NYHA Class I/II/III 10/0/0 0/14/1 0/13/2 
Haemoglobin (g/dl) - 14.4 ±1.7 14.7±1.9 
Cr Clearance (ml/min) - 100 ± 17 103 ± 23 
Comorbidities    
-systemic hypertension 0 2 0 
-diabetes 0 0 0 
-smoking history 2 6 4 
    
FEV1 (%) 97 ± 10 97 ± 15 89 ± 18 
FVC (%) 105 ± 16 104 ± 14 102 ± 16 
KCO (%) - 88.0 ± 18.7 86.8 ± 12.1 
    
RA mean (mmHg) - 4.5 ± 2.5 7.1 ± 1.9* 
RV EDP (mmHg) - 5.1 ± 2.9 8.5 ± 2.0* 
mPAP (mmHg) - 18 ± 5 40 ± 8* 
PCWP (mmHg) - 7.6 ± 3.1 9.6 ± 2.4 
PVR (dyn.s
-1
.cm
-5
) - 169 ± 80 541 ± 237* 
CI (L/min/m
2
) - 2.7 ± 0.5 2.5 ± 0.4 
SvO2 (%) - 75 ± 5 71 ± 5 
Compliance (ml/mmHg/Kg) - 0.04 ± 0.02 0.02 ± 0.01* 
6MWD  - 413 ± 86 368 ± 108 
Min SpO2 (6MWD) - 93 ± 4 92 ± 3 
NT-pro BNP (pg/ml) - 182 ± 349 789 ± 1046* 
    
Table 4.1 
Demographics of patients studied with both CPET and RHC. Data presented as mean ± sd * p < 0.05, 
unpaired Student’s T test (CTEPH vs CTED) 
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Single/Recurrent PE 
Plasmatic factors conferring risk of 
thrombosis 
    CTED (N = 15) 12/3 Idiopathic (N = 7) 
Factor II heterozygosity (N = 1) 
Low Protein C/S (N = 4) 
Factor V Leiden (N = 2) 
APC resistance (N = 1) 
CTEPH (N = 15) 9/6 Idiopathic (N = 8) 
Low Protein C/S (N = 6) 
Anticardiolipin IgG positive (N = 1) 
 
Table 4.2 
Modality of PE presentation and plasmatic risk factors by CTED and CTEPH groups. ‘Idiopathic’ 
describes no identified cause on plasmatic screen. APC = activated protein C. 
 
4.3.2 Exercise responses 
All patients exercised to symptom limitation and AT was confidently detected in all patients. Exercise 
capacity assessed by peak VO2 and peak workload was lower in the CTEPH group compared to the 
CTED group and in the CTED group compared to controls. The CTEPH group also demonstrated 
higher Vd/Vt, greater hypoxaemia, higher Ve/VCO2 slope value, steeper HR/VO2 slope and lower end 
tidal-CO2 (AT) (Table 4.3). At AT, Ve/VCO2 ratio was higher in the CTEPH group compared to the 
CTED group and controls (Table 4.3, Figure 4.2). End-tidal CO2 was lowest in patients with CTEPH 
with the greatest differentiation between groups seen at AT. Peak O2 pulse was attenuated in patients 
with CTED and CTEPH compared to controls (Figure 4.2). Arterial blood gases were obtained in 
24/30 (80%) of patients with CTED and CTEPH. For similar pH and serum lactate, PaCO2 did not 
differ between CTED and CTEPH groups. Analysis of Ve/VCO2 ratio by end-tidal CO2 and PaCO2 at 
peak exercise suggested that Vd/Vt was accountable for the difference in ventilatory efficiency in 
CTED and CTEPH (Figure 4.3). Systemic BP did not differ between groups at rest, peak exercise or 
during recovery. 
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Peak Exercise Parameter 
(unless stated) 
Controls 
N = 10 
CTED 
N = 15 
CTEPH 
N = 15 
    
    
VO2 (ml/Kg/min) 31.6 ± 10.7 20.1 ± 5.8† 15.7 ± 3.7* 
VO2 (% pred) 113 ± 35 94.1 ± 26 74.2 ± 16* 
Load (W) 186 ± 62 122 ± 34† 107 ± 37* 
RER 1.22 ± 0.10 1.15 ± 0.10 1.13 ± 0.10 
    
Ve (/min) 89 ± 27.5 80 ± 27 75 ± 26 
BR (%) 35 ± 22 27 ± 25 27 ± 29 
    
HR (/min) 169 ± 19 155 ± 20 150 ± 15 
HRR (%) 5.4 ± 17 12 ± 14 15 ± 11 
O2 pulse (ml) 13.1 ± 4.0 10.3 ± 3.5† 8.5 ± 2.6 
HR/VO2(/litre) 44 ± 12 59 ± 22† 84 ± 27* 
    
Ve/VCO2 slope 29.25 ± 6.3 37.6 ± 11.2† 46.8 ± 12.2* 
Ve/VCO2(at) 27.0 ± 4.4 37.1 ± 8.0† 45.8 ± 7.4* 
End tidal-CO2(at)(mmHg) 42.8 ± 4.5 31.4 ± 6.9† 26.5 ± 4.3* 
    
pH - 7.33 ± 0.07 7.34 ± 0.07 
pO2 (mmHg) - 89 ± 14 75 ± 15* 
pCO2 (mmHg) - 34 ± 6 35 ± 4 
Lactate - 9.7 ± 3.7 9.4 ± 3.1 
Vd/Vt (%) - 34.5 ± 11.4 50.8 ± 6.6* 
Aa O2 gradient (mmHg) - 29 ± 16 46 ± 12* 
    
 
Table 4.3 
 
Exercise response variables for patients studied by RHC and CPET and sedentary controls (no RHC 
undertaken). Data presented as mean ± sd.  RER = respiratory exchange ratio, Ve = minute 
ventilation, BR = breathing reserve, HR = heart rate, HRR = heart rate reserve, CI = chronotropic 
index, Vd/Vt = dead space fraction, Aa gradient = alveolar arterial gradient, (at) = anaerobic threshold 
* p < 0.05, CTEPH vs CTED, † p < 0.05, CTED vs Controls 
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Figure 4.2 
Ve/VCO2, end tidal CO2 and O2 pulse through phases of exercise. Black circles – CTEPH, Clear 
triangles – CTED, Clear circles – Controls 
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Figure 4.3 
Responses in Ve/VCO2 in relation to end tidal CO2 and PaCO2 at peak exercise 
 
4.3.3 Prediction of a CTEPH diagnosis 
Peak exercise Vd/Vt and Aa gradient, HR/VO2 slope, Ve/VCO2 slope, Ve/VCO2(AT) and end-tidal-
CO2(AT) discriminated strongly between CTED and CTEPH groups (Table 4.3, all p < 0.01). Vd/Vt 
showed good correlation with mPAP (r=0.66, p < 0.01). Serum NT pro-BNP had weaker 
discriminatory value (p = 0.04). Univariable predictors of a CTEPH diagnosis where the area under 
the ROC curve was significantly different from 0.50 were peak exercise Vd/Vt, Aa gradient and 
Ve/VCO2 (AT) (Figure 4.4). In a multivariate model comparison of Vd/Vt, Aa gradient and 
Ve/VCO2(AT) with serum NT pro-BNP and HR/VO2 slope, only Vd/Vt retained a significant 
predictive effect (p = 0.03 (Vd/Vt) vs p = 0.09 (Aa gradient) vs p = 0.08 (Ve/VCO2(AT)). A peak 
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exercise Vd/Vt > 45 % had a sensitivity of 92% and specificity of 83% in predicting a diagnosis of 
CTEPH. A peak exercise Aa-oxygen gradient > 32 mmHg had an equivalent sensitivity of 92% and 
specificity of 67%.  
 
 
Figure 4.4 
ROC analysis of exercise parameters comparing predictive effect for a diagnosis of CTEPH: Vd/Vt 
AUC 0.88 (CI 0.67 – 0.97), Aa gradient AUC = 0.76 (CI 0.53 – 0.90), Ve/VCO2 (at) AUC = 0.77 (CI 
0.61 – 0.92) 
 
4.4.4 Pulmonary Vascular Obstruction 
Total pulmonary vascular obstructive indices for CTED and CTEPH groups were 72.5% (60 – 80%) 
and 67.5% (55 – 70%) respectively (Table 4.4). The trend towards a lower Total Pulmonary Vascular 
Obstruction Index (indicating more obstructed vessels) in patients with CTEPH did not meet 
statistical significance (p=0.08). No patients suffered from isolated unilateral obstruction suggestive 
of an alternative diagnosis to CTED and CTEPH. 
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 Right Lung Left Lung Total TPVO Index 
CTED (N = 15) 196/300 229/300 425/600 72.5% (IQ 60 – 80) 
CTEPH (N = 15) 180/300 208/300 388/600 67.5% (IQ 55 – 70) 
   p value 0.08 
 
Table 4.4 
 
Quantification of pulmonary vascular obstruction in patients with CTED and CTEPH. Total score per 
patient = 40 including both lungs (see Chapter 2: Materials and Methods for detailed explanation of 
Total Pulmonary Vascular Obstruction (TPVO) Index) 
 
 
4.4 Discussion 
Our results describe changes in peak exercise gas exchange and ventilatory efficiency in patients with 
confirmed chronic thromboembolic obstruction following PE stratified by haemodynamic criteria 
diagnostic of PH.  Vd/Vt at peak exercise predicts a diagnosis of CTEPH in this setting with 
acceptable sensitivity and specificity. Furthermore, Aa gradient at peak exercise and Ve/VCO2 (AT) 
harbour similar predictive value. Reduced exercise capacity in CTED and CTEPH and elevated 
Ve/VCO2 ratio compared to controls appeared attributable to elevated Vd/Vt. In keeping with its 
strong predictive effect, Vd/Vt correlated well with the severity of haemodynamic derangement. On 
CT evaluation, resting haemodynamics appeared not to be influenced by the extent or distribution of 
proximal thromboembolic obstruction. This supports an additional contribution from a small vessel 
vasculopathy in patients with CTEPH and to a lesser extent in patients with CTED.  
Patients in CTED and CTEPH groups showed a similar diffusion capacity (KCo) (88 vs 87 %). This 
may be explained by the relatively mild phenotype of the CTEPH group. Different resting ventilatory 
responses in CTED and CTEPH are supported by the high discriminatory value of capillary to resting 
end-tidal CO2 gradients in CTEPH above other forms of PH (Scheidl et al., 2012). Exploring the 
origins of ventilatory inefficiency requires multiple inert gas elimination studies which were not 
available in this setting. However, at peak exercise, different VeVCO2/PaCO2 alignment between 
CTED and CTEPH groups was noted (Figure 4). This appeared to be accounted for by higher peak 
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exercise Vd/Vt although increased chemosensitivity in the CTEPH group may have contributed to this 
difference. Increased chemosensitivity has been postulated as a stimulus of exercise hyperventilation 
in PAH and chronic heart failure although its importance in CTEPH remains subject to debate 
(Chesler et al., 2009; Deboeck et al., 2004). 
The relative contributions of V/Q mismatch, inadequate cardiac output and exertional hypoxaemia 
that contribute to exercise limitation may differ between PAH and CTEPH. Vd/Vt in our study 
predicted haemodynamic outcome, a finding that persisted in a multivariable model. Accounting for 
this, it has been suggested Vd/Vt may contribute more towards ventilatory inefficiency in CTEPH 
than in other forms of PH (Zhai et al., 2011).  Gas exchange in CTEPH is likely characterised by a 
shift towards higher ventilation-perfusion ratios which may give rise to increased Vd/Vt (West, 1969). 
The normal exercise response is associated with a fall in Vd/Vt to values < 20% (Balady et al., 2010), 
hence we suggest that patients with CTED suffer a failure of adequate recruitment of the pulmonary 
vascular bed on exercise. This may occur through impaired cardiac output adaptation and ventilation 
perfusion inequality. Importantly, increased shunting was not attributable to flow through a patent 
foramen ovale in our study using criteria defined by Sun et al (Sun et al., 2002). 
In the CTED group, mild elevation in serum NT-pro BNP supports an underlying impairment in RV 
adaptation. This is also suggested by their low/normal cardiac index at RHC (2.7 ± 0.5, Table 2). 
Elevation in Ve/VCO2 ratio was noted which although milder than in the CTEPH group, closely 
mirrors the CPET response of congestive heart failure (Hollenberg and Tager, 2000). High Aa oxygen 
gradient has been shown to be explained by mild disturbance in ventilation/perfusion ratios amplified 
by a low SvO2 at rest and during exercise secondary to a low cardiac output (Dantzker and D'Alonzo, 
1985). This is in keeping with higher Aa-gradient values in our CTEPH group and values in the upper 
limit of normal in patients with CTED.  
Elevated RV afterload is also relevant to impaired RV adaptation on exercise. RV afterload 
encompasses components of resistance, compliance and wave reflection. Persistent exercise 
intolerance post pulmonary endarterectomy has been attributed to lower exercise pulmonary arterial 
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compliance despite normalisation of PVR post-operatively (Bonderman et al., 2011). In our study, 
persistent thrombus may adversely affect compliance conferring higher total afterload that is not 
incorporated by measurement of PVR. This could potentially blunt the exercise cardiac output 
response in patients with CTED. In spite of this, compliance showed no relationship to exercise 
capacity. An increase in the mPAP/cardiac output (CO) slope which relates to dyspnoea symptoms 
may perhaps have offered clearer insight (Naeije, 2013). Although not investigated, it is probable that 
the CTED group demonstrate higher than normal slope values. In future this may be best approached 
by echocardiographic measurements (Argiento et al., 2012). 
Non-invasive methods that suggest the presence of chronic thromboembolic obstruction in an ‘at-risk’ 
population are potentially advantageous. In CTEPH, exercise may be especially valuable given recent 
evidence suggesting resting echocardiographic estimation of PVR incorporating measurement of TR 
velocity may not be entirely robust (Xie et al., 2014). Although routine screening with resting 
echocardiography for CTEPH has been recommended six weeks after PE, echocardiography data 
carries little predictive value and the optimal timing of scans in symptomatic patients is yet to be 
established (Ribeiro et al., 1999). Our study is notable in that all patients with CTED and CTEPH had 
suffered prior acute PE, none were taking pulmonary vasodilator therapy and groups were age 
matched. Age-related differences in RV remodelling in CTED and CTEPH are therefore unlikely. 
Although the ideal control cohort for this study would have been a population being followed up for 
exercise limitation post-PE without chronic thromboembolic obstruction, such a group was not 
available for study. Nevertheless, we have characterised CPET responses in two conditions (CTED 
and CTEPH) that should alert clinicians to the possible presence of chronic thromboembolic 
obstruction in this clinical setting.  
Differentiation of chronic thromboembolic obstruction by haemodynamic outcome may be especially 
pertinent given surgical treatment with PEA is recently being considered for symptomatic benefit in 
patients with CTED. Following PE, exercise limitation in this group has a less clear causal 
relationship to chronic thromboembolic obstruction (Gotthardt et al., 2002). Therefore CPET may 
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help guide selection for surgery to offer maximal patient benefit by providing surrogate assessment of 
exercise cardiac adaptation. We have shown that exercise parameters inform on disease severity in our 
cohort and CPET has already been used in patients with CTEPH in the assessment of response to 
therapy (Mereles et al., 2006; Nagel et al., 2012; Pepke-Zaba et al., 2013). Further evaluation of 
exercise responses in patients with chronic thromboembolic obstruction is warranted irrespective of 
resting haemodynamics. 
Finally, in roughly one half of all patients, no prior thrombotic predisposition could be identified. This 
finding is broadly consistent with a recent international CTEPH registry (Pepke-Zaba et al., 2011). 
Biological mechanisms that predict the degree of persistent vascular obstruction following PE are 
incompletely understood. Our findings on CT reinforce the hypothesis that the extent of residual 
pulmonary vascular obstruction does not appear to be the sole mechanism responsible for the 
development of CTEPH. Impaired ‘in vitro’ fibrinolysis has been suggested as a possible mechanism 
for persistence of thrombotic material (Miniati et al., 2010; Morris et al., 2006). Furthermore, wide 
variation exists between the degrees of pulmonary vasculopathy in small vessels which, left untreated, 
may increase over time (Moser et al., 1990). Currently, definitive evidence of clinical progression 
from CTED to CTEPH is lacking. The abnormal exercise response observed in this study suggests 
patients with CTED may harbour subclinical changes in the distal pulmonary vasculature in addition 
to impaired exercise cardiac reserve. This should be evaluated in longitudinal studies.     
Despite the prospective nature of the study, there are limitations, in particular our small and highly 
selected patient group which excluded patients with COPD, LV systolic dysfunction and obesity. 
Despite CTED being a rare entity, this was necessary as these comorbidities can colour the CPET 
interpretation of exercise intolerance. Caution should therefore be exercised in extrapolating our 
results to all patients with CTED. Second, we did not measure simultaneous exercise haemodynamics 
and thus cannot comment as to whether CPET findings represent changes of exercise-induced PH. At 
present however, the prognostic significance of exercise-induced PH remains unclarified in chronic 
thromboembolic obstruction. Lastly, our study was not designed to detect the presence of persistent 
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thromboembolic obstruction following PE. Whilst modalities that avoid the use of ionising radiation 
may be clinically attractive, especially in younger populations, this would require more substantial 
patient numbers assessed at stratified intervals during anticoagulation for PE that to our knowledge 
has so far not been achieved. 
 
4.5 Conclusions  
The major finding of this study was the distinction on CPET between patients with chronic 
thromboembolic obstruction with and without PH compared to sedentary controls. The mechanism of 
exercise impairment in CTED centres on impaired RV adaptation on exercise without apparent 
significant influence from the degree of proximal thromboembolic obstruction. CPET, unlike 
routinely employed exercise assessments such as 6MWD, offers diagnostic insight into patients 
suffering persistent symptoms after acute PE. This is particularly relevant to patients with preserved 
RV function on resting echocardiography whose symptoms are rarely present at rest. 
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Chapter 5:   Whole exome sequencing in Chronic Thromboembolic 
Pulmonary Hypertension 
 
5.1 Introduction 
 
Recent advances in next generation DNA sequencing technology have greatly reduced the costs and 
feasibility of sequencing the entire genome in relation to Sanger sequencing (Metzker, 2010). Exome 
sequencing concentrates on the 5% of the genome that encodes for proteins and requires no prior 
assumptions or knowledge about the genes predisposing to the disease thus allowing unexpected 
genetic predisposition to be uncovered. Since the seminal study by Ng, this approach has led to a 
rapid expansion in the identification of genetic mutations in Mendelian disease in the last five years 
(Bamshad et al., 2011; Biesecker, 2010; Ng et al., 2010; Ng et al., 2009; Yang et al., 2013).  
 
Application of exome sequencing in complex disease has progressed more slowly. Unlike conditions 
exhibiting Mendelian inheritance, it is hypothesised that multiple DSVs contribute interactive effects 
on the phenotype. This suggests that, in complex disease,  individual DSVs may have near negligible 
effects. Nevertheless the identification of homozygous and heterozygous DSVs with predicted 
deleterious effects remains possible and strategies to enrich the phenotype under investigation may 
increase the likelihood of identifying a causative genetic defect (Cole et al., 2012). A key factor in 
increasing this likelihood is to define as closely as possible an extreme phenotype within a trait. 
CTEPH is itself an extreme phenotype but this can be further refined by identifying patients with a 
similar clinical course, and by excluding known risk factors. 
 
Mechanisms of development of CTEPH are unclear but may centre on the interplay between vascular 
inflammation, aberrant cellular proliferation and endothelial dysfunction. In a small minority of 
patients suffering PE, this leads to persistence of organised thrombotic tissue within the pulmonary 
artery (Fedullo et al., 2000; Pengo et al., 2004). In up to 30% of cases, CTEPH is diagnosed at a 
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young age with no identifiable predisposing genetic factor (Morris et al., 2006; Pengo et al., 2004). In 
these cases, a inherited predisposition towards disordered clot resolution may exist in a significant 
proportion. 
 
To date, CTEPH has not demonstrated heritable transmission and no single genetic or biological 
factor has been pinpointed to account for its epidemiology. Based on its extremely low population 
prevalence and low incidence following PE, it may be hypothesised that a proportion of cases result 
from rare genetic variation that confers a pathological effect. By exome sequencing DNA from 
unrelated individuals with a similar (and extreme) phenotype of CTEPH, all of whom have suffered 
inadequate thrombus resolution following PE, it may be possible to enrich for mutations predisposing 
to disordered clot resolution. This is in keeping with proposed mechanisms of disordered fibrinolysis 
(Morris, 2013). The finding of commonly mutated genes in unrelated individuals might therefore 
point to novel disease mechanisms.  
 
A complimentary approach is the further analysis of parental-child trios. This involves sequencing 
parental DNA of CTEPH probands in an effort to uncover de novo genetic variation (new germ line 
variants arising from the gametes of the parents). De novo DSVs have been hypothesised to harbour 
more damaging effects (Veltman and Brunner, 2012) and are subjected to less stringent evolutionary 
selection. They are therefore prime candidates for causing sporadically occurring disease such as 
CTEPH. Parental child trio analysis has been successfully used in families with Mendelian 
neurological disease to pinpoint disease causing mutations (Hamdan et al., 2013; Rosewich et al., 
2012) but is not yet established in complex phenotypes. Nevertheless, given availability of parental 
DNA in ten out of twenty CTEPH probands, de novo mutation analysis was also undertaken. 
 
This chapter presents preliminary results from whole exome sequencing experiments in twenty 
individuals with CTEPH and 10 parental child trios. All CTEPH probands were diagnosed at a young 
age following acute PE to maximise the potential genetic contribution to disease. In addition, heritable 
and environmental factors known to predispose to CTEPH were excluded as far as possible as 
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unknown genetic variation was hypothesised to be important. This Chpater’s results are presented 
chronologically as refinement of mutation analysis pipeline is under ongoing review within the 
Papworth Pulmonary Vascular Disease research group at Papworth and aspects of the analysis are 
perhaps better understood in this way. 
 
 
5.2 Case Selection 
 
Patients with CTEPH were selected for sequencing based on phenotyping that aimed to enrich for 
mutations lying within fibrinolytic pathways. This was in part based on our previous group’s 
experience suggesting fibrinolytic factors may explain a proportion of cases of CTEPH 
(Suntharalingam et al., 2008) as well as established in vitro data suggesting an association between 
dysfibrinogenaemia and CTEPH (Morris et al., 2009). Inclusion and exclusion factors are listed in 
Table 5.1 and 5.2 respectively.  
 
 
 
- Diagnosis of CTEPH as per PAH Dana Point 2008 
guidelines 
-Age < 50 
-Same sex/ethnicity (European Caucasian) 
-History of acute PE treated with anticoagulation 
-Absence of known clinical, biochemical or genetic risk 
factors for venous thromboembolism or significant co-
morbidity 
 
Table 5.1 
 
Inclusion criteria 
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-Splenectomised 
-Antiphospholipid Antibody/lupus anticoagulant 
positivity 
-Protein C and S deficiency 
-Prothrombin gene mutation 
-Antithrombin III deficiency 
-Factor V Leiden mutation positive 
-Other defined heritable defect in coagulation pathway 
-Myeloproliferative disease 
-Active or past history of neoplasia 
-(Use of HRT/oral contraceptive pill) 
-(Pregnancy or breastfeeding) 
-Congenital heart disease 
-HIV positivity 
-History of intravenous drug use 
-USS evidence of liver cirrhosis (Alcoholic or non-
Alcoholic) 
-Presence of haemoglobinopathy/chronic haemolysis 
-Other factors contributing to pulmonary hypertension 
- Moderate to severe obstructive or restrictive 
spirometry (FEV1/FVC < 50% or FVC <50%) 
- Severe congenital abnormalities of the thorax, 
diaphragm or lungs 
- Evidence of interstitial lung disease on HRCT 
Chest 
- History of OSA/sleep disordered breathing/pre-
existing abnormal sleep study 
- Congestive cardiac failure defined as impaired 
LV systolic/diastolic function on 
echocardiography 
-Chronic renal impairment (Cr clearance < 30ml/min/h) 
-History of pulmonary, renal or systemic vasculitis 
-Evidence of connective tissue disease from history or 
examination 
-All other classifications of pulmonary hypertension 
within Dana Point classification other than chronic 
thomboembolic pulmonary hypertension 
 
Table 5.2 
Exclusion criteria 
 
Samples meeting inclusion and exclusion criteria were obtained from Papworth Hospital Tissue Bank 
which is a frozen storage facility containing whole blood samples of patients under the care of the 
Pulmonary Vascular Disease Service at Papworth Hospital since 2005. Patients were selected by 
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casenote review with selection, phenotyping and whole exome sequencing of samples beginning in 
November 2011.  
 
5.3 Results 
 
5.3.1 DSV filtration – CTEPH probands 
 
Table 5.3 outlines age, sex and DNA concentrations of the 20 CTEPH probands undergoing exome 
sequencing. This included 9 males and 11 females. All patients were of European Caucasian ancestry 
and under 50 years of age at the time of blood donation. None had a positive family history for VTE. 
DNA extraction and quantification were performed as per the methods described in Chapter 2 prior to 
sample handover to EASIH for DNA sequencing. 
 
 
Identifier 
 
Sex 
 
Age 
DNA 
concentration 
(ng/μL) 
 
OD260/OD280 
     
1 M 32 72.2 1.77 
2 M 38 78.4 1.85 
3 M 39 125 1.78 
4 M 42 51.2 1.73 
5 M 47 156.6 1.72 
6 M 48 64.9 1.78 
7 M 50 58.5 1.81 
8 M 50 75.7 1.82 
9 M 44 125.1 1.80 
10 F 21 114.1 1.88 
11 F 23 115 1.78 
12 F 23 213.9 1.76 
13 F 26 123.5 1.78 
14 F 28 202.6 1.79 
15 F 34 63.6 1.79 
16 F 38 141.7 1.74 
17 F 39 144.6 1.73 
18 F 43 165.1 1.78 
19 F 43 250.2 1.75 
20 F 50 115.4 1.79 
 
Table 5.3 
Age, sex and DNA concentration of CTEPH probands 
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20 CTEPH probands were sequenced in a single dataset generated using the Agilent 50Mb All Exon 
target enrichment kit. Sequencing was undertaken on the Illumina HiSeq2000 platform by EASIH 
using a single flowcell lane on a 75 bp paired-end Illumina run. The coverage and capture efficiency 
of this dataset are shown below in Table 5.4. This highlights acceptable levels of read mapping as 
well as a degree of non-specific capture. Generally, in using Illumina short-read sequence data, a rate 
> 80% of targeted exons that exceed 20x depth coverage serves as a typical lower limit for high-
confidence DSV calls. The equivalent rate of coverage for 20 CTEPH probands was 66.5% for this 
sequencing run. 
 
 
 
 
 
 
 
 
 
 
 
 
Table 5.4 
 
The average coverage in the target region is defined as the total number of bases mapped within the 
target region 
 
 
The finding of common DSVs in multiple unrelated probands was the final goal of the initial analysis. 
To this end, several bioinformatic filters were applied through GATK to prioritise DSVs by 
pathogenicity, inheritance and novelty. DSVs were filtered for pathogenicity by first selecting only 
protein-encoding DSVs. As target bait coverage incorporated within Agilent’s exome capture 
technology is known to include intronic regions, protein-coding regions of the genome were 
prioritised at outset. Secondly, only those protein-encoding DSVs with predicted deleterious effects 
(though to be pathological) were taken forward. These DSVs were defined by the following 
classifications of transcript variant: splice site, frameshift coding, non-synonymous coding, NMD 
 CTEPH probands (20 samples) 
Average Percent 
Mapped Reads 1.24x10
8
 98.9 
Unmapped Reads 1.58x10
6
 1.1 
Reads aligned to reference 
genome 
4.92x10
7
 87.5 
On bait bases 2.19x10
9
 - 
Off bait bases 4.02x10
8
 - 
Baits with 10x coverage - 82.5 
Baits with 20x coverage - 66.5 
Baits with 30x coverage - 51.3 
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transcript, within-mature miRNA, STOP-codon gained, STOP-codon lost and essential splice site. 
Pathological DSVs were subsequently grouped by heterozygosity/homozygosity under an autosomal 
dominant/autosomal recessive model of inheritance respectively.  
 
Further filtration was undertaken to prioritse novel DSVs that is, those DSVs not present within 
publically available genetic databases. The rationale for this step was that CTEPH is currently 
unaccounted for by existing DSVs. Three databases were used for screening DSVs: dbSNP137, 
Exome Sequencing Project 6500 and the 1000 Genomes Project (1Kg) and population prevalences of 
DSVs, where known, were established across all databases. 
 
Table 5.5 shows DSV numbers categorised by classification, inheritance and MAF. Rare DSVs were 
those present in 1Kg at low population frequency (MAF < 1%) based on European Caucasian 
ancestry. DSVs were labelled ‘novel’ if not present in the latest version of dbSNP 137. 
  
Table 5.5 
 
Number of total and ‘rare’ DSVs passing quality control (QC) appearing in all 20 CTEPH probands. 
Results are then segregated by Heterozygosity (Het), homozygosity (Hom) and novelty. Note the 
same DSV may be present in multiple probands hence the large absolute number in each class. 
 
 
This table demonstrates that numerous rare DSVs are undescribed within dbSNP137 and therefore 
novel by our definition. This included > 4000 rare SNPs under an autosomal dominant model and 
  
QC filtered 
Rare (MAF < 0.01) known and 
novel variation 
  
Het Hom Het Hom 
SNP Known 387887 262811 48874 38368 
 
Novel 4111 130 4052 88 
INS Known 1476 676 657 329 
 
Novel 15 2 15 1 
DEL Known 2045 786 802 451 
 
Novel 17 0 17 0 
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over 80 under an autosomal recessive model. This list was long to be able to select candidate DSVs 
for further analysis. To concentrate results at the gene rather than the DSV level, a list of commonly 
mutated genes arising from CTEPH probands is also presented in Table 5.6. This list was obtained by 
filtration for pathogencity and comparison against dbSNP137 to exclude previously described DSVs  
with subsequent omission of genes containing those DSVs. Results are split by heterozygous and 
homzygous alleles. 
 
RSS1 14 APOBEC3H 5 SLC25A6 3 PRSS3 3 
TRBV6-5 12 MPP4 5 BCORL1 3 KRBA1 3 
PRIM2 10 FAM163A 5 EPDR1 3 GPER 3 
BRD8 9 MUC1 5 PRSS2 3 ZAN 3 
ATP6V1A 9 NR4A3 5 TRBV4-2 3 IGLV3-22 3 
RETSAT 9 TRBC2 5 GPR98 3 SPEG 3 
SGK2 8 NEFH 5 TMEM161B 3 PRDM15 3 
FRG1B 8 RIMS4 5 ENSG00000205785 3 KRTAP29-1 3 
ENSG00000186399 8 KIR3DX1 4 MAGI1 3 KRTAP4-5 3 
KRT75 7 PPCS 4 YEATS2 3 B4GALT2 3 
MUC6 7 FAM194B 4 ATP9B 3 ATP8A2 3 
MUC5 7 ANO4 4 APCDD1 3 SRGAP1 3 
TTN 7 ENSG00000215615 4 MRC2 3 USH2A 3 
C12orf51 7 FAM120A 4 TMEM132E 3 SLC45A3 3 
FOXRED1 7 FOXK1 3 COTL1 3 ENSG00000179571 3 
ENSG00000239262 7 TRBV6-7 3 ENSG00000138600 3 PRDM2 3 
RABGAP1 7 BRD8 3 MEF2A 3 ATXN7L2 3 
BZRAP1 7 CACNA1I 3 HOMEZ 3 EIF2S3 3 
DMXL2 7 CSF2RB 3 GAS6 3 AKAP17A 3 
C1orf163 7 VWA3A 3 ITPKB 3 P2RY8 3 
IPO5 6 FMR1 3 TNN 3 MPP1 3 
MCM8 6 PION 3 TCP11L1 3 ASMTL 3 
GRIK3 6 GIMAP6 3 PPP2R3B 3 ERMP1 3 
ZNF706 6 EPHA1 3 ARSD 3 MTUS1 3 
 
(Heterozygous) 
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STM1 7 PPCS 5 CRIPAK 5 
KRTAP5-7 6 RPF1 5 ENSG00000229924 5 
ENSG00000251537 6 OR6M1 5 FOXF2 5 
TSPYL6 6 HNRNPA1P30 5 PIP5K1P2 5 
PRPF4B 6 RBM23 5 TUSC3 5 
C6orf138 6 CACNA1G 5 LCN1P2 5 
BZW2 6 BAIAP2L2 5 ENSG00000212857 4 
PIP5K1P2 6 PLA2G6 5 ENSG00000212847 4 
TUSC3 6 PDE6B 5 MXRA5 4 
KIR2DL5B 6 FAM153A 5 ITGB1BP2 4 
LPCAT1 6 CAMK2B 5 PABPC5 4 
 
(Homozygous) 
Table 5.6 
Genes containing common DSVs with predicted pathological effect (heterozygous and homozygous 
allele models). The columns (left to right) represent the affected gene and the number of samples in 
that gene which contain one or more novel, pathogenic variants. This analysis focuses on variation at 
the gene level rather than on specific DSVs. Ensembl references (ENS) are given where no gene 
nomenclature has been defined. 
 
 
No further analysis of individual DSVs from CTEPH probands was proposed at this stage; instead, 
further sequencing of parental samples was undertaken. This decision was supported by a number of 
factors. As previously discussed, recent literature highlighting a relative excess of rare genomic 
variation (due to recent population expansion) suggested exome sequencing in complex disease with a 
rare population frequency (<10 cases/100,000) may require in excess of 1000 samples to achieve 
statistical significance at the individual DSV level (Tennessen et al., 2012). This suggested our small 
sample (n = 20) was likely to be underpowered in its ability to statistically segregate DSVs. Secondly, 
our read alignment tool, BWA, pointed towards several DSVs with predicted damaging effects that 
were not reproduced using other read aligners. In particular, a known limitation of BWA is its weak 
annotation of copy number variations (CNVs) despite it reporting mapping quality scores that can be 
used to discard unsupported mappings. Realignment with another alignment tool, Novoalign 
(Novocraft, 2010), suggested several DSVs may have been been incorrectly called. Finally, and 
perhaps most significantly, raw sequencing data from the 20 CTEPH probands suggested a relatively 
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low read depth coverage (20x coverage depth in 66.5% of exons) meaning the power of our analysis 
to call all functionally relevant DSVs may be significantly reduced.  
 
Sequencing of DNA from the parents of 10 of 20 CTEPH probands was therefore undertaken. Ten 
sets of both parents were consented under a Rare Disease Cohort study (Bioresource, Cambridge) 
which allows the collection of volunteer samples. Samples were anonymised so as to prevent tracking 
of familial genetic predisposition not relevant to CTEPH. Importantly, all sequenced parents of 
affected probands had no history of thromboembolic disease (acute or chronic). This is consistent with 
the lack of heritibility in CTEPH and absence of pro-thrombotic risk factors in CTEPH probands. 
DNA was extracted from saliva samples donated by parents and sequenced in December 2012. The 
exome capture kits (Agilent V1.3), enrichment techniques and sequencing platform were the same as 
were used for proband sequencing.  Parental sequencing was completed in January 2013. 
 
5.3.2 Quality Control and Read Mapping Statistics 
Pooled coverage and capture efficiencies of both cohorts are shown in Figure 5.1.  
Figure 5.1 
Mean target coverage for CTEPH probands (A67 red) and parents (B94 green) with pooled datasets 
(grey). 
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This data shows a comparison of target capture between index cases and parental cohorts and 
highlights a significant discrepancy. In index cases, an inadequate depth of coverage (mean 66.5% 
20x depth) has been achieved potentially limiting variant calling. Figure 5.2 shows the number of total 
and mapped reads for CTEPH probands (left half - A67) and twenty parents (right half - B64). This 
shows, in all but one case (sample B640014), greater than 50 million mapped reads per run which is 
the minimum acceptable threshold for exome analysis. Sample B640014 was re-sequenced following 
this finding. 
Figure 5.2 
Mapped reads (millions) across all 40 sequenced individuals. Left half – CTEPH probands, right half 
parental samples 
 
The discrepancy in read mapping statistics between index cases and parents (Table 5.7), on more 
detailed exploration was explicable by a higher fraction of PCR duplicates in CTEPH probands 
(Figure 5.3). PCR duplicates are produced during PCR amplification in DNA library preparation and 
occur because the same reads are overamplified. Although an imbalance in PCR duplicates may arise 
from deeper sequencing in one cohort compared to another, the marked discrepancy was thought to be 
attributable to PCR slippage. PCR slippage is encountered particularly in areas of the genome rich in 
repetitive sequences of adenine-thymine (AT) or guanine-cytosine (GC) base pairs. These base pair 
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combinations produce low thermodynamic stability resulting in the polymerase being less able to 
anneal to a template. PCR duplicates may be removed bioinformatically from the final analysis but 
represent a large fraction of non-informative sequencing data resulting in significant limitations in the  
dataset. 
 
Table 5.7 
Comparison of read mapping statistics for CTEPH probands and parental samples. The target 
coverage and depth was markedly better for parental samples. 
  
 
 
Figure 5.3 
 
PCR duplication rates across index cases (A67 samples – left side of graph) and parents (B64 
samples- right side) 
 CTEPH index cases 
(20 samples) 
CTEPH parents  
(20 samples) 
Average Percent Average Percentage 
Mapped Reads 1.24x10
8
 98.9 7.92x10
7
 98.5 
Unmapped Reads 1.58x10
6
 1.1 1.21x10
6
 1.5 
Reads aligned to reference 
genome 
4.92x10
7
 87.5 6.51x10
7
 90.1 
On bait bases 2.19x10
9
 - 4.31x10
9
 - 
Off bait bases 4.02x10
8
 - 8.32x10
8
 - 
Baits with 10x coverage - 82.5  88.9 
Baits with 20x coverage - 66.5  81.6 
Baits with 30x coverage - 51.3  74.2 
Bases aligned to reference in 
reads mapped at high quality 
8.34x10
9
 - 7.10x10
9
 - 
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5.3.3 Variant Calls 
De novo DSVs arising from the parental child sequencing are shown in Table 5.8.  
6 ZNF678 2 GLTSCR1 1 SARDH 1 LILRB5 1 CEL 
6 SRP68 2 ESPNP 1 RYR1 1 LILRA6 1 CDC42EP1 
6 ANKRD36 2 CYP26B1 1 RSPH4A 1 LCP2 1 CCNC 
5 SPI1 2 CPSF1 1 RGSL1 1 LCNL1 1 CAPZA3 
5 HLA-DRB5 2 CIC 1 RBMX 1 KPTN 1 C17orf70 
4 KRI1 2 CCDC85B 1 RBM15B 1 KIAA1715 1 C17orf100 
4 AK128833 2 BCLAF1 1 RBKS 1 KIAA0125 1 BRD4 
3 TTC21B 2 BAI1 1 PP14571 1 KCNK15 1 ATP4A 
3 SOGA2 1 ZSCAN10 1 PLEC 1 KCNJ12 1 ARIH2OS 
3 SAMD4A 1 ZNF83 1 PLCH1 1 ITGB2 1 ANKS3 
3 MUC6 1 ZNF703 1 PLCB3 1 IL33 1 ANGPTL4 
3 ITGAE 1 ZBTB46 1 PKM 1 HLA-H 1 ALG3 
3 HOOK1 1 WNT10B 1 PIGQ 1 HLA-DQB1 1 AHRR 
3 HLA-B 1 WDR81 1 PHLPP1 1 GPR20 1 ADCY5 
3 ANO8 1 VWA5B2 1 PER1 1 GPHN 1 ADCY10 
3 AHNAK2 1 VWA3B 1 PDZD4 1 GABRA3 1 ADAMTS9 
2 TTC9B 1 UNC13D 1 PDDC1 1 FUK 1 ADAMTS7 
2 TARBP1 1 UBXN11 1 OTOG 1 FIBP 1 ABCA13 
2 SNAPC4 1 UBE2C 1 OR4C3 1 FCGBP 
  
2 SCN7A 1 TTN 1 OR12D3 1 FBXO2 
  
2 SCAPER 1 TRPM2 1 NYAP1 1 FBRSL1 
  
2 RETSAT 1 TRAPPC12 1 NTN3 1 FAM46C 
  
2 POLDIP2 1 TRABD2B 1 NR4A3 1 ERI3 
  
2 MYRF 1 TRA 1 NPHP4 1 DUSP2 
  
2 MUC12 1 TP73 1 NOTCH2 1 DRD4 
  
2 MICA 1 TMPRSS13 1 MYO9A 1 DOCK7 
  
2 MAMDC4 1 TMEM145 1 MUC4 1 DOCK2 
  
2 LRP5 1 SSH2 1 MRGPRX3 1 DNAH7 
  
2 LONP2 1 SPTA1 1 MFRP 1 DLGAP1 
  
2 LINC00273 1 SPSB4 1 MCM3AP 1 DBX2 
  
2 KRT18 1 SPON1 1 MAP1S 1 CUX1 
  
2 KCNB1 1 SPEG 1 MAG 1 COL18A1 
  
2 ICOSLG 1 SORBS3 1 LRSAM1 1 CHD5 
  
2 HLA-DRB1 1 SKA3 1 LRFN2 1 CFHR5 
  
2 HLA-A 1 SELPLG 1 LOC653513 1 CELA1 
    
Table 5.8 
List of genes containing de novo DSVs arising from the analysis of ten parental-child trios under and 
autosomal dominant model. The number associated with each gene corresponds to the number of de 
novo DSVs within that gene appearing in the ten CTEPH probands. 
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Some de novo mutations were shared across multiple unrelated samples (for example ZNF678, SRP68 
and ANKRD36). In total, 158 genes containing de novo DSVs emerged from 10 parental child trios 
giving 15.8 genes per trio. The absolute number of de novo DSVs was 232 and not in keeping with 
previous trio analyses which more commonly quote between 0 – 3 de novo DSVs arising per trio. 
Reasons for this discrepancy in output are discussed further below. 
 
As well as grouped data, individual genetic targets were interrogated by visual inspection with a 
genome browser (Integrated Genomics Viewer, IGV). For example, read depth coverage of the 
angiogenic factor, Vascular Endothelial Growth Factor A (VEGF-A) is shown in Figure 5.4. This 
demonstrates maternal inheritance of a single DSV lying within an intronic region q16.1. Although 
VEGF-A is intimately linked to angiogenesis, this variant transpired to be neither pathogenic nor 
novel. 
 
Figure 5.4 
IGV screenshot of a parental-child trio genotypes in VEGF-A.  Proband (top), maternal (middle) and 
paternal (bottom) genotype suggest a maternal variant (lower red arrow) differing from the reference 
genome that is inherited in the proband (top red arrow). Other variants in the maternal copy are not 
inherited (black arrows). 
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Vascular Endothelial Zinc Finger – 1 (VEZF-1) (Figure 5.5), also related to angiogenesis, was also 
found to contain a 6 base pair insertion that resulted in an extension of a polyglutamine (Q) tract. 
Polyglutamine extensions in large number have been commonly associated with inherited movement 
disorders such as cerebellar ataxia and Huntingdon’s chorea. However, this variant despite being 
annotated as novel, was not reproduced with Novoalign suggesting it had been called artefactually. 
 
 
 
Figure 5.5 
 
IGV screenshot of parental-child trio genotypes in VEZF-1, important to angiogenesis and cellular 
proliferation. Despite good target coverage, placement of a 6 base pair extension (TTGTTG - red 
circle) in different locations of a polyQ tract within this gene results in different DSV calls using 
alternative alignment tools. 
 
 
 
 
5.3.4 Grouped analysis of fibrinolytic genes 
 
In further attempt to support or refute a fibrinolytic origin in CTEPH, an analysis was undertaken 
looking at numbers of DSVs lying within genes known to lie within fibrinolytic pathways in probands 
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and parents. These genes were identified by a keyword search for “fibrinolysis” in Genecards, 
(Weizmann Institute of Science) which is an online searchable, integrated, database of human genes 
that provides concise genomic related information, on all known and predicted human genes. This 
resulted in 140 candidate genes against which the list of DSVs from probands and parents could be 
cross-referenced (Appendix 5.1). No discrimination was made between common or rare DSVs in this 
analysis. Simply, the number of DSVs was calculated as a proportion of the total number of DSVs 
passing QC for probands and parents. The rationale for this was that an excess proportion of 
deleterious DSVs in fibrinolytic genes in probands compared to parents would support a 
preponderance of risk in CTEPH lying within fibrinolytic genes. Results are shown in Table 5.9. 
 
 
 
 
 
 
 
 
Table 5.9 
Comparison of DSVs in proband and parental samples for all genes as well as for ‘fibrinolytic’ and 
‘fibrinolytic and damaging’ subsets. Boxes describe the number of DSVs in each category with the 
percentage of the total number of DSVs in brackets. Note, in this representation, DSVs are shared 
between probands and between parents and are therefore not shown in absolute number. Polyphen 
was used to predict downstream damaging effects on proteins and DSVs classified as ‘possibly’ and 
‘probably’ damaging were included. Chi-square test for univariate frequency distributions was used to 
compare an expected frequency of DSVs (parents) with the observed frequency (CTEPH probands) 
across all groups. 
 
These results show broadly similar DSV numbers in probands and parents for all genes and genes 
lying within fibrinolytic pathways. CTEPH probands and parents also harbour similar numbers of 
fibrinolytic DSVs that are predicted to be damaging to downstream proteins – roughly 10% of the 
‘fibrinolytic’ DSV pool. 
 
DSVs sequenced  
CTEPH 
probands 
Parents 
All genes 25292 25466 
Fibrinolytic genes 1153 (4.6%) 1145 (4.5%) 
Fibrinolytic and 
Damaging 
114 (9.9%) 110 (9.6%) 
Pearson Χ2 1.39 p = 0.49 
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5.4 Discussion 
 
 
The use of whole exome sequencing is at an early stage in complex disease genetics. Although 
prioritised to targeting coding regions of the genome where sequence variation is assumed to have 
more important effects, this technique has a high potential for false positive and false negative results. 
Sequence data quality was suboptimal in this study with an inadequate depth of coverage in CTEPH 
probands most likely attributable to a high proportion of duplicated reads. This places non-trivial 
restrictions on the robustness of conclusions despite DSV numbers broadly reflecting those achieved 
in exome sequencing studies with similar designs (Cole et al., 2012). 
 
The selection of candidate DSVs through bioinformatic filtration requires assiduous care. In 
particular, prioritisation of ‘pathogenic’ and ‘novel’ DSVs by the exclusion of those appearing within 
common databases of genetic variation (dbSNP) is controversial; dbSNP is known to include both 
common and rare ‘pathological’ DSVs. Furthermore, complex phenoypes are less well defined with 
their genetic contribution unestablished within public databases. This study hypothesised the 
aetiology of CTEPH to be attributable to rare genetic variation given its low population prevalence 
and extreme nature of the phenotype. However, the assumption that rare variants (prioritised by MAF 
< 0.01) carry greater pathogeneic potential stems from predictive modelling and to date has not been 
validated within complex phenotypes. In addition, the role of rare DSVs is highly likely to vary by 
disease (Carr et al., 2013; Larson and Schaid, 2014; Stitziel et al., 2011). Following on from this, 
methods to statistically segregate DSVs are non-standardised and no formal consensus exists on the 
best method to define statistical association in complex disease. This study did not incorporate a large 
control or replication cohort as there were doubts over sequencing data quality. For similar reasons, 
adjustment for gene size which has strong implications on mutation frequencies was not undertaken. 
These restrictions apply not only to individual DSV lists but also the grouped analysis. 
 
Akin to the second hit hypothesis implicated in the development of IPAH (Liu and Morrell, 2013), 
mutations in CTEPH may only carry functional effect following the occurence of a prior event (such 
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as an acute PE). As PE at young age is rare in population terms, CTEPH could conceivably be 
attributable to common genetic variation. This may compromise the use of exome sequencing as a 
strategy to identify underlying genetic predispostion as it inherently prioritises rare and undescribed 
variants. Potentially, CTEPH could be investigated by whole genome sequencing to interrogate both 
common and rare DSVs occuring in both coding and non-coding regions. Non-coding regions can 
harbour important regulatory function in protein transcription and their ommision using exomes may 
therefore overlook important pathogenic variants. However, presently both the cost and rarity of 
CTEPH samples preclude such work without considerable collaborative effort. 
 
The significant advantage of parental-child trios is the opportunity to uncover de novo mutations. In 
sporadic diseases with no heritable trend, this mutation class is hypothesised to explain a larger 
majority of the genetic burden (Vissers et al., 2010). Significantly our trio analysis produced a 
relatively higher nmber of de novo DSVs, far greater than numbers found in previous studies (Sanders 
et al., 2012; Xu et al., 2011). De novo variation represent the most extreme form of genetic variation 
with their occurence varying considerably depending on genomic location, paternal age and local 
sequence content. The latter may be particularly dependant on DSV proximity to CpG islands 
(Shiraishi et al., 2002). Perhaps more importantly, proband and parental DNA was not sequenced 
simultaneously as samples were collected nearly one year apart. Although exome capture was similar 
between cohorts, it is unclear how this factor accounts for the increased number of de novo DSVs in 
this analysis. 
 
De novo occurence of mutations, although more likely to be causative for sproadic disease, 
importantly do not represent sufficient evidence of disease causation by themselves; the frequency 
and distribution of mutations require further characterisation in matched unaffected controls. 
Currently, data analysis techniques in whole exome sequencing are in rapid evolution and are most 
challenging when applied to complex disease genetics. Importantly, exome studies do not completely 
bridge the gap between rare variant association and disease causation without further functional 
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characterisation of downstream effects. However, the emergence of candidate genes in unstudied 
complex diseases would represent an important step forward. 
 
Pathway-based segregation of DSVs by predicted functional effect is not a new approach in exome 
analysis but is novel within CTEPH. In this analysis, an equal fraction of damaging DSVs was present 
within fibrinolytic pathways in probands and parents suggesting equally deleterious mutations existed 
in these cohorts. These results fail to support a putative role for defective fibrinolysis in CTEPH over 
and above genes lying within non-fibrinolytic pathways. This result may be considered surprising as 
probands were deliberately phenotyped with this mechanism of disease in mind. Of note, parental 
sequencing produced a similar proportion of non-synonymous DSVs within fibrinolytic genes. This 
finding perhaps supports a ‘second hit’ hypothesis in CTEPH suggesting the differentiating factor 
between probands and parents is not their genetic architecture but instead an environmental factor, 
such as the occurrence of PE. Isolated VTE has been investigated with a large GWAS that has 
suggested minor increases in risk of VTE for small numbers of SNPs (Heit et al., 2012). Large studies 
such as this are crucial if ultimately a candidate gene approach is to be adopted in CTEPH, assuming 
large enough numbers of patients can be sequenced.  
 
 
Appendix 5.1 
 
CPB2 SERPINE1 F12 HRG KLKB1 SERPINB8 SERPINB10 SERPINI2 SERPINF2 PLAT THBD 
SERPINC1 FGA PLG PPBP PF4 PLAU TAF1 F2 SULT1A3 F5 F11 SERPINB2 ELANE F3 TAT 
VWF F10 PROC F7 PWAR1 F8 TFPI ANXA2 APOH MMP10 APOA1 SERPINA5 CPA6 PROS1 
C1S CPB1 HABP2 PLAUR LPA NF2 KLK1 CPA1 TTPA F2RL2 RIPK4 PPIC CLEC3B RARRES2 
PDGFB FGB SERPING1 ANGPT2 SELP KNG1 ALOX12 CPN1 KRT1 SAA1 TMPRSS6 USF1 
CPA3 ORM1 F2R F9 VTN CRP INS ITGB2 FN1 SDC1 FGG PTGIS EPO GP1BA CELSR2 
SERPINI1 CHKA FAP IL6 ALB AGTR1 CTSB SELE F13A1 TIMP1 GPT IL1RN CD40 ITGAM 
IGFBP7 SERPINA3 SERPINE2 LEP APOB CTSD THBS1 IL1R1 DES SERPINA1 IL18 TRAF3 
A2M MB EDN1 ADIPOQ TNF ACE MAP2K1 ENO1 HMGCR NRP1 IGF2R REN IL1A SST GH1 
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SOD1 IL1B MAPK8 MMP9 FGF2 MTHFR PRL ADAMTSL1 EGF IL2 IL8 IL10 IL1RAPL2 APP 
MAPK1 TGFB1 IFNG VEGFA 
 
Candidate gene list obtained from ‘Genecards’ for ‘fibrinolysis’ keyword search 
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Chapter 6. Patient-reported outcomes assessed by CAMPHOR 
questionnaire predict clinical deterioration in Chronic Thromboembolic 
Pulmonary Hypertension and Idiopathic Pulmonary Arterial Hypertension 
 
 
6.1 Introduction 
 
CTEPH and IPAH are rare conditions which despite available treatments display overall poor survival 
but with heterogeneity in individual prognosis (Galie et al., 2009c). IPAH has traditionally been 
perceived as a progressive disease with uniformly poor outcome but improving trends in survival are 
emerging, suggesting that advances in medical therapy or greater diversity in patient phenotype may 
be responsible (Benza et al., 2012; Keogh et al., 2011). In CTEPH with a proximal distribution of 
thrombotic obstructions, PEA strongly impacts survival with surgery that restores haemodynamics to 
normal levels almost analogous to cure in the most expert hands (Mayer et al., 2011). However, in 
patients with a distal distribution of disease and in those experiencing functional limitation and 
persistently abnormal haemodynamics following PEA, outcomes are less well characterised. 
 
Prognostic factors, both invasive and non-invasive, form a cornerstone of PAH management and are 
relevant both to medical therapy and transplantation referral (Gupta et al., 2011; Swiston et al., 2010).
  
Individually however they behave inconsistently in estimating prognosis. As such their use has been 
supplanted by examining panels of clinical data, taking into account multiple disease factors (Galie et 
al., 2009b). None of these specifically include patient-reported outcome measures (PROMs) or 
measures of a patient's health-related quality of life (QoL). These are typically short, self-completed 
questionnaires and can be either generic or disease specific. In healthcare services they are 
increasingly perceived as a robust method of measuring treatment outcomes that are important from a 
patient perspective. Using PROMs for prognostic evaluation is a novel area in PH although there is a 
burgeoning interest in their use for other chronic lung diseases (Braido et al., 2011). Although generic 
PROMs may lack sensitivity in monitoring changes in single patients, there are advantages in 
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applying disease-specific versions including trying to better understand the complex relationship 
between treatment efficacy and patient outcomes particular to certain diseases.  
 
The most widely studied PROM in PH is the Cambridge Pulmonary Hypertension Outcome Review 
(CAMPHOR) (McKenna et al., 2006), a PH-specific measure of health-related QoL. It is a 
questionnaire comprising three sections evaluating symptoms, activity levels and QoL and has 
undergone international validation in patients with PH of multiple aetiologies (Chua et al., 2006; 
Cima et al., 2012; Ganderton et al., 2011; Gomberg-Maitland et al., 2008). Furthermore it has shown 
good correlation with the Medical Outcomes Study 36-item short form (SF-36) and the six minute 
walk distance (6MWD) (Gomberg-Maitland et al., 2008). 
 
This study aimed to broaden the current clinical application of CAMPHOR and hypothesised that 
scores would have prognostic value both in CTEPH and IPAH. Our primary aim was to determine 
whether baseline CAMPHOR scores predicted clinical deterioration (CD) in these diseases. Our 
secondary aims were to evaluate CAMPHOR’s prognostic value when repeated over time and the 
additional value it provided at diagnosis after adjustment for the prognostic influence of NYHA Class 
and 6MWD.  
 
 
6.2 Methods 
 
This study was a retrospective analysis of data obtained from the Pulmonary Vascular Disease Unit 
database at Papworth Hospital between 2004 and 2012 corresponding to eight years of CAMPHOR 
use in our practice. All patients provided written informed consent in completing questionnaires. Data 
collection for this study was under the approval of the local research ethics committee (Huntingdon) 
who approved the use of CAMPHOR within a PH population from 2004 onwards (REC reference: 
H02/805). 
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6.2.1 Study Population: Inclusion and Exclusion criteria 
 
The study population consisted of incident cases of CTEPH and IPAH between May 2004 and end 
March 2012. All patients must have undergone RHC satisfying the most contemporaneous World 
Symposium on PH criteria at diagnosis and be over 16 years. Patients with CTEPH consisted of two 
subgroups. The first subgroup comprised patients with a distal distribution unsuitable for PEA. The 
second comprised patients with continued functional limitation receiving targeted PH treatment when 
found to have persistently elevated mPAP (>=25 mmHg) at RHC at least 3 months post PEA. These 
are referred to as ‘residual’ within the CTEPH group.  
 
Patients were excluded in the following circumstances: a proximal distribution of CTEPH treated by 
PEA, a change in diagnosis following initial assessment, prescription of targeted therapy predating the 
first CAMPHOR assessment, patients who died during their first admission, failure to complete 
CAMPHOR alongside assessment of 6MWD and NYHA, failure to meet the threshold for treatment 
under the national guidelines. The contribution of excluding factors is outlined in Figure 6.1. 
 
6.2.2 Questionnaire 
 
The CAMPHOR questionnaire contains 65 items in total, 25 relating to symptoms, 15 relating to 
patient’s activity and 25 relating to QoL. It is negatively weighted; a higher score indicates worse 
QoL and greater functional limitation. Symptom and QoL items are both scored out of 25; “yes/true” 
scores 1 and “no/not true” scores 0. Activity items have three possible responses (score 0-2): giving a 
score out of 30. Each CAMPHOR assessment takes on average 10 minutes. 
 
 
6.2.3 Outcome variables 
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The primary outcome was CD defined as hospital admission with symptoms of right heart failure, 
escalation of targeted therapy, transplantation, atrial septostomy, or death. CD was quantified from 
time zero taken as the first diagnosis of PH contemporaneous with initiation of targeted treatment for 
patients with distal CTEPH and IPAH. In the residual CTEPH group, time zero was taken from first 
assessment at least three months following PEA. In total there were 5 patients lost to follow up and 
these patients were censored at the last visit date. All patients were treated as per National UK 
standards of care for PH (National Pulmonary Hypertension Centres of the and Ireland, 2008) and 
follow up continued until all patients clinically deteriorated or until censoring at the end of data 
collection (23
rd
 March 2012). 
 
 
 
 
Figure 6.1 
Patient pathway showing numbers screened, excluded, enrolled and those experiencing CD 
 
6.2.4 Statistical Analysis 
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Patients diagnosed CTEPH and IPAH were analysed. Baseline information at time zero was 
summarised as mean and SD or frequency counts and proportions. CAMPHOR scales were analysed 
as total scores as well as each subcategory.  There are no standard cut-offs for categorising total 
CAMPHOR score or CAMPHOR subscales. For Kaplan Meier plots total CAMPHOR score was split 
into 4 equal sized categories 0-19, 20-39, 40-59, 60-80 and subscales were split into 3 roughly equal 
sized categories; 0-8, 9-17 and 18+ for symptom and QoL and 0-9, 10-19 and 20+ for activity. 
 
Time from treatment initiation to CD/censoring in the different categories was summarised on 
Kaplan-Meier plots with comparisons between categories by log-ranks tests. Univariable and 
multivariable Cox regression was used to assess independent risk predictors. Hazard Ratios and 95% 
confidence intervals were calculated to a 5% significance level. The association between CD and 
longitudinal information from CAMPHOR and clinical measures at 4 months and yearly intervals was 
analysed using univariable Cox regression with time-updated covariates, for missing covariate values 
the last measurement was carried forward. 20% and 24% of CTEPH and IPAH patients respectively 
had at least one prognostic factor missing at baseline. Missing baseline values were likely to be 
missing at random therefore missing values were imputed using multiple imputation to assess the 
robustness of the estimates from the complete case analysis. Since these analyses gave very similar 
results only the complete case analysis is included here.  
 
 
6.3 Results 
 
138 CTEPH patients and 105 IPAH and were screened with 112 and 87 respectively enrolled in the 
study. Patients were excluded for different reasons in CTEPH and IPAH groups (Figure 6.1). Baseline 
demographics, CAMPHOR scores and clinical data are shown in Table 6.1. Mean age in the IPAH 
group was lower and pulmonary haemodynamics were more severe. Total CAMPHOR scores and all 
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subscales were higher in the IPAH group consistent with worse self-assessment of symptoms. Notably 
6MWD did not differ significantly at enrolment. Figure 6.1 shows the breakdown of CD for each 
group and demonstrates the majority of CD were a consequence of escalation of targeted therapies. In 
the CTEPH group, 49 of the total of 62 CD events occurred in the distal group and 13 in the residual 
group. 28/74 (38%) died in the distal group during the study compared to 7/38 (18%) in the residual 
group. 
 
 
Table 6.1 
 
Comparison of baseline characteristics 
 
Neither gender nor age was associated with an altered risk of CD nor did age significantly affect the 
interval to CD during follow up. Freedom from CD was higher for patients with CTEPH up to 5 years 
after enrolment, after which it was similar to that for patients with IPAH (Figure 6.2). Survival was 
Variable 
Units 
/Categories 
CTEPH patients 
(n=112) 
IPAH patients 
(n=87) 
Mean Age  61.4 (14.8) 55.7 (16.3) 
Age range  17 – 86 18 – 81 
mPAP 
(mmHg) 
Mean (S.D) 45.8 (11.8) 49.6 (10.5) 
Missing 2 9 
PVR Mean (S.D) 10.5 (5.6) 13.8 (5.0) 
(Dyn) Missing 14 22 
Gender Male 44 (39%) 35 (40%) 
 Female 68 (61%) 52 (60%) 
Total CAMPHOR 
score 
Mean (S.D) 33.0 (16.8) 39.9 (17.2) 
Missing 17 13 
Symptom score 
Mean (S.D) 11.7 (6.2) 13.8 (6.2) 
Missing 15 12 
Activity score 
Mean (S.D) 11.5 (6.2) 13.9 (7.2) 
Missing 16 12 
QoL score 
Mean (S.D) 10.0 (6.5) 12.0 (6.3) 
Missing 17 13 
6MWT (metres) 
Mean (S.D) 277.7 (119.0) 271.9 (112.7) 
Missing 6 7 
NYHA 
Class 
2 22 (20%) 8 (9%) 
3 83 (74%) 61 (71%) 
4 7 (6%) 17 (20%) 
Missing 0 1 
Type 
Distal 74 (66%) - 
Residual 38 (34%) - 
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consistent with recent international registries with no difference between the CTEPH and IPAH 
cohort (Figure 6.3) (Humbert et al., 2006; Thenappan et al., 2007). 
 
*Logrank Test P value 
Figure 6.2 
 
Kaplan- Meier plots displaying the cumulative proportion free from CD over the follow up period 
 
 
 
 
 
 
 
 
 
*Logrank test P value 
Figure 6.3 
 
Kaplan-Meier survival plots for both cohorts 
*p=0.036
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6.3.1 Univariable analysis 
 
In both CTEPH and IPAH groups baseline measurements of total CAMPHOR scores, all subscales 
and a higher NYHA Class were independent predictors of CD (Table 6.2). Haemodynamics mPAP 
and PVR also showed some predictive value. QoL scores between 0 – 8 and 9 – 17 showed similar 
rates of CD although a QoL score greater than 18 was associated with significantly higher rate of CD 
(Appendix 6.1 – page 121). In the CTEPH group, CD was significantly related to total CAMPHOR 
score and all CAMPHOR subscales (Figure 6.4a). In patients with IPAH, CD was significantly 
associated with higher categories of total CAMPHOR score and symptom and activity scores (Figure 
6.4b). QoL scores between 0 – 8 and 9 – 17 showed similar rates of CD although a QoL score greater 
than 18 was associated with significantly higher rate of CD (Figure 6.5). A higher baseline 6MWD 
predicted a reduced likelihood of CD in both CTEPH and IPAH with a 50m increase associated with a 
significantly reduced hazard across the study population (Table 6.2). A total of 66 and 90 patients in 
the IPAH and CTEPH groups had total CAMPHOR, NYHA and 6MWD at baseline. 
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Table 6.2 
 
Univariable Cox proportional hazards models for clinical deterioration with baseline measurements as 
covariates. *Likelihood ratio test P value. **QoL unit score increase for CTEPH patients and 
categories for IPAH patients. 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Logrank test P value 
Figure 6.4a 
Kaplan- Meier plots displaying the cumulative proportion free from CD over the follow up period 
for different categories of total CAMPHOR at baseline for CTEPH patients 
 
 
 CTEPH patients  IPAH patients  
Variable 
Units 
/Categories 
HR (95% CI) 
P 
value* 
HR (95% CI) 
P 
value* 
Total 
CAMPHOR 
Unit score 
increase 
1.04 (1.02 – 1.06) <0.001 1.03 (1.01 – 1.05) 0.001 
Symptom 
Unit score 
increase 
1.12 (1.07 – 1.18) <0.001 1.09 (1.04 – 1.14) 0.001 
Activity 
Unit score 
increase 
1.12 (1.07 – 1.17) <0.001 1.06 (1.02 – 1.11) 0.002 
QoL** 0 – 8 
1.07 (1.03 – 1.12) 0.001 
- 
0.046  9 – 17 0.73 (0.38 – 1.40) 
 18 – 25 1.79 (0.90 – 3.53) 
NYHA 2 - 
 
0.013 
- 
0.007  3 2.67 (1.25 – 5.70) 1.59 (0.62 – 4.07) 
 4 3.57 (1.06 – 12.06) 4.00 (1.42 – 11.27) 
6MWD 50m increase 0.79 (0.70 – 0.89) <0.001 0.84 (0.75 – 0.95) 0.004 
mPAP 
(mmHg) 
5 mmHg 
increase 
1.15 (1.03 – 1.29) 0.013 1.10 (0.96 – 1.25) 0.170 
PVR 
(Dyn) 
 
200 Dyn  
increase (2.5 
Wood Units) 
1.12 (0.99 – 1.27) 0.075 1.20 (1.04 – 1.38) 0.015 
Type Distal - 
<0.001 
- - 
 Residual 0.37 (0.20 – 0.69) - - 
*p<0.001
0
.0
0
0
.2
5
0
.5
0
0
.7
5
1
.0
0
P
ro
p
o
rt
io
n
 f
re
e
 f
ro
m
 C
W
7 4 2 2 1 0 0Total score 60 - 80
23 15 12 7 6 2 1Total score 40 - 59
44 35 26 20 14 5 4Total score 20 - 39
21 21 18 14 12 9 2Total score 0 - 19 
Number at risk
0 1 2 3 4 5 6
Time since commenced medication (years)
Total score 0 - 19 Total score 20 - 39
Total score 40 - 59 Total score 60 - 80
115 
 
 
 
 
 
 
 
 
 
 
 
 
*Logrank test P value 
Figure 6.4b 
 
Kaplan- Meier plots displaying the cumulative proportion free from CD over the follow up period for 
different categories of total CAMPHOR at baseline for IPAH patients 
 
 
 
6.3.2 Multivariable analysis 
 
The multivariable modeling adjusted for the effect of NYHA class and 6MWD at baseline is shown in 
Table 6.3. In the CTEPH group, baseline symptom score and total CAMPHOR were of independent 
value with no significant effect seen from activity or QoL. Only a high QoL score provided an 
independent predictive effect of CD for patients with IPAH. Given CAMPHOR is correlated to 
6MWD and NYHA, when both are adjusted for, the effect of each subscale is notably diluted. Further 
adjustment for mPAP and PVR increases the association of total CAMPHOR and it’s subscales with 
CD (Appendix 6.2 – page  123) but these results should be interpreted with caution due to the low 
number of patients and CD events. 47 and 78 patients in the IPAH and CTEPH groups had total 
CAMPHOR, NYHA, 6MWD, mPAP and PVR at baseline.  
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*Likelihood ratio test P value. **QoL unit score increase for CTEPH patients and categories for 
IPAH patients 
Table 6.3 
 
Multivariable Cox proportional hazards models adjusted for NYHA and 6MWD for clinical 
deterioration with baseline measurements as covariates 
 
 
 
 
6.3.3 Longitudinal analysis 
 
Longitudinal analysis of total CAMPHOR scores, its subscales and 6MWD showed a direct 
association with CD (Table 6.4). NYHA Class was not analysed as a time-updated covariate as 
patients rarely changed class. The similar regression coefficients using Cox regression (Table 6.2) and 
time-updated covariates (Table 6.4) suggest that isolated CAMPHOR assessments over time add little 
to its predictive effect on CD determined at enrolment and that the effect of CAMPHOR does not 
change over time.  
 
 
 
 
 
 CTEPH patients IPAH patients 
Variable 
Units 
/Categories 
HR (95% CI) P value* HR (95% CI) P Value* 
Total 
CAMPHOR 
Unit score 
increase 
1.03 (1.00 – 1.05) 0.027 1.02 (0.99 – 1.05) 0.158 
Symptom 
Unit score 
increase 
1.08 (1.02 - 1.15) 0.006 1.05 (0.98 - 1.12) 0.143 
Activity 
Unit score 
increase 
1.06 (1.00 - 1.13) 0.067 1.04 (0.98 - 1.10) 0.227 
QoL** 0 – 8 
1.03 (0.98 – 1.09) 0.210 
- 
0.005  9 -17 0.37 (0.16 - 0.84) 
 18 -25 1.14 (0.47 - 2.78) 
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*Logrank Test P value 
Table 6.4 
 
Univariable Cox proportional hazards models with CAMPHOR scores as time updated covariates 
 
 
6.4 Discussion 
 
The current clinical application of CAMPHOR focuses on evaluation of patient perceptions in PH. 
We have shown for the first time a novel use for the CAMPHOR questionnaire obtained at diagnosis 
in its ability to predict CD in patients with CTEPH and IPAH. Similar to NYHA Class and 6MWD, 
both total CAMPHOR score and its subscales appear to act as risk predictors suggesting CAMPHOR 
may have prognostic importance. Following adjustment for 6MWD and NYHA Class, some 
predictive effect persists and further adjusting for haemodynamics, mPAP and PVR, increases the 
association of total CAMPHOR and it’s subscales with CD.  This may be explained by the loss of 
heterogeneity between CTEPH and IPAH after adjustment for NYHA, 6MWD, mPAP and PVR, 
leaving a clearer association between CAMPHOR and CD. 
 
In keeping with existing knowledge, a lower 6MWD and higher NYHA Class at enrolment were 
associated with greater risk of CD. Gender had no significant effect. Contrasting with other studies, 
age did not predict rate of CD in either CTEPH or IPAH cohorts (Benza et al., 2012; Galie et al., 
2008b; Hoeper et al., 2005b).
 
 This is most likely explained by our definition of CD being different 
  CTEPH patients IPAH patients 
Variable Units/Categories HR (95% CI) 
P 
Value* 
HR (95% CI) 
P 
Value* 
Total 
CAMPHOR 
score 
Unit score 
increase 
1.04 (1.02 – 1.05) <0.001 1.04 (1.02 – 1.06) <0.001 
Symptom 
Unit score 
increase 
1.11 (1.06 – 1.15) <0.001 1.11 (1.06 – 1.16) <0.001 
Activity 
Unit score 
increase 
1.12 (1.07 – 1.16) <0.001 1.08 (1.04 – 1.12) <0.001 
QoL 
Unit score 
increase 
1.08 (1.04 – 1.12) <0.001 1.08 (1.03 – 1.13) <0.001 
6MWD 50m increase 0.75 (0.67 – 0.84) <0.001 0.81 (0.73 – 0.91) <0.001 
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from that used in other interventional studies in that we did not incorporate a reduction in 6MWD or 
maintenance of NYHA Class within our CD criteria, both of which may act as more sensitive 
indicators of CD with advancing age (Howard, 2011).
 
We intentionally chose our definition of CD in 
part because not all clinical measures were documented at each visit, the poor inter-observer 
correlation of NYHA Class assessment and because CD could have occurred without a 6MWD being 
undertaken if patients were too unwell. In spite of this the similar survival trends to large registries 
points to the observed rates of CD with advancing age being a genuine effect (Humbert et al., 2010; 
Lee et al., 2012).
 
 
Total baseline CAMPHOR is an 80 point scale so that a one unit increase is a small difference and 
unlikely to be clinically relevant. A more meaningful increase of 10 points on the total CAMPHOR 
scale has a univariable HR of 1.37 (1.14 – 1.64) for CTEPH and 1.51 (1.27 – 1.79) for IPAH, giving a 
51% and 37% increase in the incidence of CD respectively. Whilst baseline total CAMPHOR scores 
demonstrate a significant predictive effect of CD in both CTEPH and IPAH, exceptions arise within 
subscales of CAMPHOR when analysed in isolation. For QoL within the IPAH cohort, the hazard 
ratio behaves non-linearly with an inferred protective effect against CD for QoL scores between 9-17 
which reverts to a detrimental effect for scores of 18 or above. This is in contrast to trends 
demonstrated by symptom and activity scores.  
 
Comparison between disease groups also suggests different CAMPHOR subscales harbour different 
predictive value. QoL of all three CAMPHOR subscales is the most likely to be subject to 
confounding. It is known that factors such as age, gender, education and income may impact on QoL, 
the contributions of which could not be encompassed within this study (Hopman et al., 2009). 
Similarly, feelings of depression, anxiety and hopelessness are well captured within QoL (McCollister 
et al., 2010). Although the small age and gender difference between groups, may account for some of 
the observed trends, we speculate that differing modes of presentation may affect risk of CD 
determined by CAMPHOR. Patients with IPAH generally experience more indolent onset of 
symptoms which may allow time for ‘protective’ lifestyle adaptations. The relatively abrupt onset of 
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CTEPH however, often predated by an acute embolic event, may precipitate different illness 
perceptions at first presentation.  
 
Importantly, decisions to increase treatment would have been made following patient assessment 
using 6MWD and other assessment tools. CAMPHOR scores were collected and reviewed after any 
clinical decision was made meaning scores would not have affected treatment decisions and thus CD. 
Notably, the majority of CD events arose from escalation of targeted therapies in both CTEPH and 
IPAH cohorts. Differing trends in treatment of these diseases in the UK make cross-cohort 
comparison of rates of CD difficult to interpret as IPAH benefits from several licensed drug classes 
with more scope for escalation of treatment in the face of a poor response to an initial treatment agent. 
By contrast CTEPH has more limited licensed treatments and treatment with PAH licensed therapy is 
recommended generally only within clinical drug trials. Furthermore, UK treatment guidelines differ 
to European guidelines as treatment in the UK is driven more by overall clinical impression of PH 
physicians rather than targeted treatment towards fixed goals in functional capacity (Hoeper et al., 
2005b).
 
 Obtaining an equivalent prescription of targeted therapies may therefore be impossible to 
achieve between IPAH and CTEPH in the face of clinically apparent patient deterioration although at 
baseline, data on targeted therapies prescribed within our cohorts (Appendix 6.3 – page 123) suggest 
similar treatment strategies between CTEPH and IPAH.  
 
Survival did not differ significantly between CTEPH and IPAH cohorts. Deaths contributed more 
towards CD in the CTEPH group but a similar proportion of patients with IPAH died after an 
alternative CD event. Almost one third of our CTEPH cohort consisted of patients post-PEA 
presenting with persistent functional limitation. Clinical experience suggests that patients in this 
category exhibit more stable clinical courses compared to those with distal CTEPH and there are 
almost certainly differences in pulmonary circulatory responses that govern prognosis following 
major operative intervention (Freed et al., 2011). Although combining these two groups may therefore 
seem artificial, our primary intention in this study was to evaluate the prognostic power of patient 
perceptions using CAMPHOR and so for this reason their amalgamation is justifiable. 
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PAH therapies are generally licensed for symptomatic benefit based on studies using 6MWD as a 
surrogate for symptomatic change. The use of PROMs to monitor patients is appropriate as patients 
are primarily treated for symptoms as patients will often trade years of life for good quality life. The 
finding that CAMPHOR may also offer prognostic information should therefore be seen as an added 
benefit. Although lacking direct physiological links as a marker of cardiopulmonary function, 
CAMPHOR is patient-centred in contrast to more traditional assessment tools which as a group may 
be subject to observer variability and confounding factors. Given its highly disease-specific 
derivation, it may therefore have a novel use in selected populations with PH.  
 
Despite a relatively large patient number, our study does have limitations. Cox regression used in our 
statistical analysis assumes constant risk ratios for predictive variables throughout the duration of a 
patient’s follow up which may not clinically apply to our patients. In addition, clinical need 
determined the follow-up intervals. Therefore, longitudinal analysis was hampered by time-updated 
covariate measurements not being present.  
 
 
6.5 Conclusions 
 
Existing non-invasive parameters used in prognostic assessment in PAH have recognised limitations 
and this study has sought to broaden the application of a patient-centred assessment in PH. Recently 
published UK prognostic equations that derive risk scores in PAH may accurately predict survival but 
they still rely on invasive tests (Lee et al., 2012). Increasing attention is now turning towards the 
physical and emotional implications of living with incurable disease and CTEPH and IPAH 
populations should not be regarded as exceptional (Chen et al., 2008). The relatively limited response 
to PAH targeted treatments with persistent high mortality rate makes the clinical incorporation of 
patient perceptions into long term care an attractive step forward in an emerging era of goal-oriented 
therapy.   
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Appendix 6.1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Kaplan- Meier plots displaying the cumulative proportion free from CD over the follow up period or 
different categories of the CAMPHOR subscales at baseline – CTEPH patients 
*p=0.015
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Kaplan- Meier plots displaying the cumulative proportion free from CD over the follow up period 
for different categories of the CAMPHOR subscales at baseline – IPAH patients 
 
*p=0.001
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Appendix 6.2 
 
Multivariable Cox proportional hazards models adjusted for NYHA, mPAP, PVR and 6MWD for 
clinical deterioration with baseline measurements as covariates. *Likelihood ratio test P value. **QoL 
unit score increase for CTEPH patients and categories for IPAH patients. ***CTEPH- symptom- N= 
80 (44 got CD), activity- N= 79 (44 got CD), QoL and total- N= 78 (43 got CD) 
 
Appendix 6.3 
Targeted Therapy at Baseline IPAH n=87 
 
CTEPH n=112 
 
n(%) 
 
n(%) 
Ambrisentan 0(0) 
 
1(0.9) 
Bosentan 38 (44) 
 
42 (37.5) 
Epoprostenol (IV) 9 (10.3) 
 
2 (1.7) 
Epoprostenol (IV) & Bosentan 1 (1.1) 
 
0 (0) 
Iloprost (nebulised) 6 (6.9) 
 
4 (3.6) 
Iloprost (nebulised) & Sildenafil 1 (1.1) 
 
0 (0) 
Sildenafil 26 (29.8) 
 
51 (45.5) 
Sitaxentan 4 (4.6) 
 
1 (0.9) 
Trial drug 2 (2.3) 
 
11 (9.8) 
Baseline targeted therapies for CTEPH and IPAH cohorts 
 
 
 
 IPAH patients 
(N=47 (31 CD events)) 
CTEPH patients*** 
Variable Units 
/Categories 
HR (95% CI) P value* HR (95% CI) P value* 
Total 
CAMPHOR 
Unit score 
increase 
1.05 (1.01 – 1.09) 0.005 1.04 (1.01 – 1.07) 0.004 
      
Symptom Unit score 
increase 
1.11 (1.02 - 1.20) 0.013 1.11 (1.04 – 1.18) 0.001 
      
Activity Unit score 
increase 
1.11 (1.02 - 1.20) 0.009 1.07 (1.00  1.15) 0.052 
      
QoL** 0 – 8 - 0.012 1.06 (1.00 – 1.12) 0.049 
 9 -17 0.36 (0.12 – 1.08) 
 18 -25 1.38 (0.45 – 4.24) 
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Chapter 7: General Discussion 
 
The work presented in this thesis encompasses several different approaches in attempt to further our 
understanding of chronic thromboembolic disease in humans. These include the application of 
invasive historical techniques used to study RV function, high throughput sequencing of patient DNA 
in the investigation of existing and novel disease mechanisms in CTEPH and the evaluation of 
patient-reported outcomes. CTEPH is positioned at the most extreme end of the thromboembolic 
spectrum where the RV is subjected to chronic pressure overload. From the outset, a primary 
hypothesis of the exome sequencing study suggested CTEPH develops from the co-ordinated 
interplay between genetic and environmental factors. However, emergent from the physiological 
studies is the striking heterogeneity in phenotype of patients with chronic thromboembolic 
obstruction. Proximal and distal CTEPH are established and separate clinical entities despite being 
indistinguishable pathologically. However, based on more detailed interrogation both at rest and on 
exercise, the RV demonstrates clear physiological variation in performance even within these 
phenotypes. In recent years, attention has refocused on the crosstalk between the RV and pulmonary 
circulation, intrinsically linked by properties of pulsatile flow in the pulmonary artery. Development 
of tools describing this interaction that ideally translate more easily into clinical use, will allow RV 
myocardial biology to be increasingly related to its downstream function. 
 
Long term follow up studies have uniformly demonstrated that in one third to two thirds of patients 
suffering acute PE, perfusion recovery may be incomplete even years after the initial insult. However, 
thromboembolic obstruction in this setting fails to exclusively lead to symptomatic impairment raising 
questions over its functional importance. Chapter 3 describes a study of RV and pulmonary 
circulatory performance during this clinical period and using pressure volume catheterisation, the RV 
is shown to behave abnormally, most notably during diastole. Akin to the ischaemic cascade in the 
LV, diastolic impairment may signify early RV decompensation although this study does not provide 
firm evidence for this. Instead, RV adaptation is demonstrated that occurs within a normal 
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haemodynamic spectrum. Whilst this highlights important deficiencies in PVR as a descriptor of RV 
afterload, the clinical significance of RV adaptation remains unclear. Intrinsic myocardial dysfunction 
may be responsible for the observed RV changes. Alternatively, RV adaptation may signify early 
pathological embarkation towards RV hypertrophy. Such speculation requires serial follow-up and, as 
yet, it is not proven that patients with CTED deteriorate over time. Although pressure volume 
catheterisation has clear value in load-independent contractile assessment, its lower patient 
acceptability and expense mean any longer-term studies of RV adaptation are more likely to be 
pursued using non-invasive methods. 
 
Early RV adaptation may be further investigated by molecular methods. Myocardial remodeling is 
regulated by hypertrophic and inflammatory gene expression and is known to be triggered by hypoxia 
and stress-activated pathways within the myocardium. Capacity for remodeling also demonstrates 
both inter and intra-species variation with no uniform threshold for its development identified to date. 
RV myocardial biopsies were beyond the ethical limits of this study but represent an attractive 
direction in which to further this work. Of particular interest would be the pattern of gene up-
regulation in hypertrophic pathways in myocardial tissue exposed to varying degrees of pressure 
overload. This could potentially incorporate those patients found to have ‘subclinical’ RV adaptation 
on pressure volume assessment. Previous studies involving biopsies of RV myocardium have been 
hampered by the lack of standardised protocols for timing of biopsies within the disease course and by 
inconsistency in RV biopsy location in the myocardial wall. However, detailed patient phenotyping 
offered by pressure volume assessment may enable patients with early RV adaptation to be selectively 
targeted to improve our understanding of changes in the myocardial genetic profile. 
 
In spite of an inferior patient acceptability, the merits of invasive cardiac catheterisation are notable 
during an era which has seen a paradigm shift toward non-invasive imaging modalities for RV 
functional assessment. This is in the main due to their improved image resolution and ability to 
perform serial assessments to track disease progression. RV ejection performance is determined by a 
number of factors: preload, afterload, RV wall thickness and contractility and in keeping with most 
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cardiac diseases, prognosis in all forms of PH is principally determined by myocardial dysfunction 
conferred by the property of contractility. In this regard, the conductance catheter demonstrates a clear 
advantage over non-invasive imaging; its capacity to measure dynamic ventricular volumes 
throughout the cardiac cycle. Assessment of RV volume is one of the most basic evaluations of RV 
function, currently best assessed by CMR although bedside 3D echocardiography may soon supplant 
this. Nevertheless, continued investment in invasive techniques that have a proven track record in RV 
contractile physiology, still appear warranted. 
 
Chapter 4 used CPET to evaluate functional impairment in patients with thromboembolic obstruction. 
CPET has found a foothold in the PH clinic in the last ten years providing ancillary information on 
exercise limitation above and beyond the 6MWD. However, a lack of standardised CPET protocols 
within clinical trials has perhaps hampered its wider application in the PH clinic. This study suggests 
that in patients with persistent symptoms post PE, both an exercise gas exchange deficit and RV 
insufficiency contribute to exercise intolerance. Furthermore, CPET predicts abnormal resting 
haemodynamics with acceptable levels of stringency. Stratification of patients at risk of PH and 
earlier identification of a pulmonary vascular cause of exercise limitation are important objectives in 
patients being followed up for persistent symptoms post PE. Use of an exercise approach in this 
context may potentially avoid the need for ionising radiation which is advantageous in younger 
populations. Importantly, this study was limited by its highly selected population in whom 
radiological characteristics were predetermined prior to enrolment. The lack of simultaneous exercise 
haemodynamics also limit conclusions on the recruitable RV contractile reserve given RV pressure 
flow responses can vary on exercise. However, in the presence of chronic thromboembolic obstruction 
and apparent preservation of resting RV systolic function on echocardiogram, CPET represents a 
useful addition to the clinical assessment that could potentially indicate early deterioration in RV 
function. 
 
High throughput sequencing in CTEPH represents a high risk strategy for isolating novel disease 
mechanisms and the sequencing of unrelated individuals to look for genetic disease origins is yet to 
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bear fruit in complex phenotypes. The premise of a novel genetic aetiology in CTEPH was based 
largely on its extremely low population prevalence and apparent evolution from defective fibrinolysis. 
However, a fibrinolytic origin is often contested in CTEPH pathogenesis as increasing evidence for 
the role of inflammation and angiogenesis has come to light. Exome sequencing requires an entirely 
unbiased approach to variant filtration especially when sequencing unrelated individuals in a disease 
with no predefined heritability. From the outset, patients were chosen on the basis of prior occurrence 
of PE, therefore inherently pre-selecting a major thrombembolic co-factor. A complimentary approach 
to control for the occurrence of prior PE may have involved sequencing individuals with CTEPH with 
no prior VTE episode or alternatively, a patient cohort with documented symptomatic and 
radiological resolution of abnormalities within three months of treatment for acute PE. However, 
neither of these groups was available for study within the ethical confines of this work. 
 
CTEPH may be attributable to very rare mutations in a small number or variety of genes; however, 
our patient number appears to have been inadequate to identify causative mutations. Exome 
sequencing of unrelated individuals has to date only been applied successfully using small numbers of 
patients with Mendelian diseases. Furthermore, these patients have had much more clearly defined 
phenotypes with limited heterogeneity. Multiple interacting genes have the potential to dilute the 
genetic signal in complex diseases and results from the CTEPH probands produced lists of candidate 
genes that were too long for further investigation. However in future, this sequencing data could be 
combined with exome sequencing data from larger numbers of individuals with CTEPH and Biobanks 
to perform a stronger case-control analysis. 
 
Comparison of fibrinolytic DSVs in probands and parental samples did not highlight a preponderance 
of damaging mutations as a likely contributor to CTEPH aetiology. Although damaging fibrinolytic 
mutations did exist in CTEPH probands, none were novel and therefore were unlikely to represent an 
unknown genetic predisposition. The trio approach was useful in that de novo mutations are purported 
to be more damaging that inherited variants. However, our study appeared to be numerically 
underpowered (ten parental child trios) given a recent study evaluating de novo mutations in non-
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familial schizophrenia sequenced in excess of 50 affected trios and over 20 controls to identify 40 de 
novo mutations (Xu et al., 2011). Diseases attributable to de novo genetic variation exhibit relative 
stability in their global incidence. At present however, the epidemiology of CTEPH has been 
insufficiently characterised to either support of refute this hypothesis. 
 
Finally, Chapter 6 described a retrospective analysis of the predictive value of the CAMPHOR on 
prognosis in two forms of PH. This study potentially has the furthest reaching consequences as 
prognostic markers provide invaluable guidance in treatment planning in PH. Of note, traditional 
markers of poor prognosis, including abnormal haemodynamics, functional class and 6MWD are 
shown to be no more valuable than those gleaned from simple patient questionnaires at diagnosis. 
This emphasises the value of patient perceptions in patients with PH and as a predictive model 
suggests that patient reported outcomes should form part of routine practice in all PH patients. In 
patients in whom invasive haemodynamic monitoring is not feasible, clinicians can feel increasingly 
confident that the CAMPHOR tracks disease progression more closely than is perhaps widely 
perceived. 
 
In summary, this thesis tackles several aspects of pulmonary vascular function with attempt to 
uncover novel mechanisms in the aetiology and physiological monitoring of CTEPH. RV functional 
adaptation may be further understood through continued appreciation of historical RV assessment 
methods in combination with up to date non-invasive techniques. The underlying genetic architecture 
of CTEPH warrants continued investment with multiparalleled sequencing through collaborative 
approaches involving greater patient numbers. 
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